No retraction, correction or concern found when last checked on Oct 22, 2026.

Strategies to Improve Antimicrobial Utilization with a Special Focus on Developing Countries

Brian Godman, Abiodun Egwuenu, Mainul Haque and 31 more

Life · 2021 · Review · CC BY

Abstract

Antimicrobial resistance (AMR) is a high priority across countries as it increases morbidity, mortality and costs. Concerns with AMR have resulted in multiple initiatives internationally, nationally and regionally to enhance appropriate antibiotic utilization across sectors to reduce AMR, with the overuse of antibiotics exacerbated by the COVID-19 pandemic. Effectively tackling AMR is crucial for all countries. Principally a narrative review of ongoing activities across sectors was undertaken to improve antimicrobial use and address issues with vaccines including COVID-19. Point prevalence surveys have been successful in hospitals to identify areas for quality improvement programs, principally centering on antimicrobial stewardship programs. These include reducing prolonged antibiotic use to prevent surgical site infections. Multiple activities centering on education have been successful in reducing inappropriate prescribing and dispensing of antimicrobials in ambulatory care for essentially viral infections such as acute respiratory infections. It is imperative to develop new quality indicators for ambulatory care given current concerns, and instigate programs with clear public health messaging to reduce misinformation, essential for pandemics. Regular access to effective treatments is needed to reduce resistance to treatments for HIV, malaria and tuberculosis. Key stakeholder groups can instigate multiple initiatives to reduce AMR. These need to be followed up.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 22, 2026. Paragraph numbers are ours, so an answer can point at one.

1. Introduction

1Antimicrobial resistance (AMR) is a high-priority area across all countries, increasing morbidity, mortality and costs, with several studies documenting the clinical and economic impact of AMR. There is considerable resistance to commonly prescribed antibiotics among low- and middle-income countries (LMICs) including Bangladesh, with resistance rates continuing to rise across countries. Rising AMR rates need to be urgently addressed, with the World Bank (2017) believing that even in a low-AMR scenario, the loss on world output due to AMR could exceed US$1 trillion annually after 2030, and potentially up to US$3.4 trillion annually, unless addressed, equivalent to 3.8% of annual Gross Domestic Product (GDP)—with the costs of AMR appreciably exceeding those of the antibiotics prescribed.

2Rising AMR rates are due to a number of factors including rising antimicrobial utilization especially in LMICs, with the overuse of antimicrobials linked with increasing AMR. Alongside this, the availability of substandard, spurious or falsified antibiotics, high rates of self-medication especially in LMICs often for self-limiting diseases, the extensive use of antimicrobials to prevent and treat diseases in animals considering that their manure is often used in food production and for aquaculture, water pollution, lack of hand hygiene and proper sanitation as well as travelling between countries enhances AMR rates. In their recent paper, Van Boeckel et al. (2019) found nearly a 3-fold increase in bacteria showing resistance above 50% to antimicrobials in chickens and pigs in LMICs between 2000 and 2018, with resistance rates expected to rise unless addressed.

3Low vaccination rates against disease have also enhanced antimicrobial use and AMR, with current concerns that vaccination rates are being further compromised by the COVID-19 pandemic, with its resultant impact on patient movement and available facilities as a result of lockdown and on other measures, exacerbated by vaccine hesitancy generally alongside misinformation. We are though seeing approaches to combat this including mobile vaccination clinics.

4The general overuse of antimicrobials has been worsened by the COVID-19 pandemic, with concerns with differential diagnosis between infections such as tuberculosis (TB) and bacterial upper respiratory tract infections (URTIs) from influenza, coughs, fever and COVID-19. Published studies suggest that over 70% of patients with COVID-19 received antibiotics, including broad-spectrum antibiotics, even when not clinically indicated. Typically, less than 10% of COVID-19 patients appear to have bacterial or fungal infections, with some studies suggesting that only 3.2% of COVID-19 infections are co-infections warranting antibiotics. In their recent meta-analysis, Langford et al. (2021) found that overall three-quarters of patients with COVID-19 were prescribed antibiotics, which is significantly higher than the estimated prevalence of bacterial co-infections. Consequently, the authors concluded that unnecessary antibiotic use is high in patients with COVID-19, which will enhance AMR rates.

5Concerns with rising AMR rates and the consequences have resulted in international, regional, national, and local strategies to try and reduce the rises. National initiatives include National Action Plans (NAPs) under the direction of the WHO, building on its Global Action Plan. We are already seeing countries assess their progress of NAPs against agreed targets, and this will continue.

6Alongside this, there are concerns with multi-resistant microorganisms and the implications for patients with TB, human immunodeficiency virus (HIV), malaria, and typhoid, as well as those with co-infections. Early treatment for patients with co-infections with HIV and drug-resistant TB is essential to reduce the significant risk of death. There is also ongoing research to better predict patients with MDR-TB and improve future care. Treatment centers, especially in rural areas, are important to monitor treatment progress and provide access to medicines, to enhance successful management and reduce future cases.

7Overall, we are aware that coordinated activities among all key stakeholders can address over-utilization of antibiotics. Multiple demand-side measures including education of all key stakeholders, prescribing restrictions, and follow-up in pharmacies stabilized or reduced the utilization of antibiotics in former Soviet Union republics including Azerbaijan, the Republic of Srpska, Bosnia and Herzegovina, and Slovenia versus Poland that failed to instigate such measures. In Poland, there was a small but statistically significant average annual increase in total antibiotic consumption between 2007 and 2016.

8We are also aware that there are concerns with high prevalence rates of hospital-associated infections (HAIs) in a number of LMICs, with major challenges surrounding the appropriate use of antibiotics to reduce surgical site infections (SSIs). The instigation of ASPs in hospitals, including undertaking point prevalence surveys (PPS) to identify areas for quality improvement programs, can improve future antibiotic use and reduce AMR. There are though manpower and resource challenges with implementing ASPs in hospitals in LMICs. Having said this, successful ASPs have been introduced in hospitals in LMICs to improve antimicrobial prescribing providing guidance to others. Successful programs have also been introduced in ambulatory care in LMICs to improve prescribing and dispensing of antibiotics for essentially viral infections such as acute respiratory infections (ARIs) and including URTIs. We are also seeing new technologies being developed, including Apps, to provide prescribing advice and other information to physicians and patients to reduce inappropriate use of antibiotics. However, there are concerns with variable adherence to guidelines, possibly exacerbated by guidelines not always considering local resistance patterns, as well as other activities such as community engagement to improve patient care in practice.

9We would like to build on these issues and challenges to discuss potential ways to decrease future AMR rates among LMICs. We have chosen LMICs as they currently have the greatest increase in antimicrobial use, the highest rate of self-purchasing of antibiotics, as well as the highest rate of antimicrobial use in hospitals. In addition, mortality rates from AMR are likely to be highest among LMICs, including those in Africa and Asia, by 2050 unless addressed. Effectively tackling AMR is crucial for the future of all countries, exacerbated by few new antibiotics currently being developed; however, this is counterbalanced to some extent by developments in vaccine technology. We hope our review paper will consolidate current knowledge in key areas to provide guidance on potential ways forward among all key stakeholders across LMICs to reduce AMR rates, especially where there are continued concerns.

2. Materials and Methods

10We undertook a narrative review of published papers to document potential ways to enhance appropriate prescribing and dispensing of antimicrobials. We purposely did not undertake a systematic review as an appreciable number of these have already been conducted on different aspects to improve future prescribing and dispensing of antimicrobials. In addition, we did not document the number of publications by country and sector as we are aware that some countries are more prolific in their publications than others, and such analyses may bias the actual situation. We did though divide initiatives up into those directed at hospitals compared with those in ambulatory care. We are aware that issues such as self-purchasing of antibiotics are especially important in LMICs as up to 100% of pharmacies in these countries dispense antibiotics without a prescription despite legislation which can account for up to 93% to 100% of all dispensed antibiotics. This because our principal aim was to provide possible future guidance to all key stakeholder groups within LMICs for potential debate based on the considerable experiences of the co-authors from multiple LMICs. We have successfully used this approach before to stimulate debate in other priority healthcare areas to provide future guidance.

11The World Bank classification was used to break countries down into LMICs or upper income countries where applicable. Similar to previous studies conducted by the co-authors, upper-income countries will only be commented upon where pertinent. This is because we are aware that there are different practices and beliefs, as well as a greater availability of healthcare professionals and resources, in higher- versus middle- and low-income countries. In addition, in LMICs, the costs of medicines can account for up to 60% or more of total healthcare expenditure, much of which will be out of pocket, with potentially catastrophic consequences for families when members become ill.

12There can also be long waiting times for patients to see physicians in primary healthcare centers (PHCs) in LMICs, long distances to travel to PHCs, and pharmacists are typically open later in the day, resulting in patients often seeking their advice as alternatives to physicians. This is helped by the fact that community pharmacists are typically trusted by patients and less expensive than physicians, with patients not having to pay physician fees when the need arises. However, we are aware that there can be concerns with the knowledge of pharmacists and their assistants regarding antibiotics and AMR.

13When documenting interventions that have been undertaken to enhance appropriate prescribing and dispensing of antimicrobials, we will break these down into the 4Es to enhance understanding and comparisons, namely Education, Engineering, Economics and Enforcement. Education includes developing guidelines or formularies, with adherence to well-constructed guidelines increasingly seen as demonstrating good quality care. This also includes educational and monitoring activities surrounding the WHO AWaRe list of antibiotics. Instigating Drug and Therapeutic Committees (DTCs) and ASPs in hospitals to provide educational activities to enhance the rational use of medicines including antimicrobials is also classified as education. Engineering includes organizational or managerial interventions which incorporate prescribing and quality targets. These include the percentage of antibiotics prescribed according to agreed guidance and the WHO AWaRe list, the percentage of patients not prescribed prolonged antibiotics to prevent SSIs as well as the percentage of patients reaching agreed target blood pressure levels. Economics includes financial incentives to physicians, pharmacists, patients or hospitals, for instance providing financial incentives to hospitals to improve their patient safety records and/or reduce payments where there are concerns, incentivizing physicians for attaining agreed prescribing targets including adherence to guidelines, or fining pharmacists for illegally dispensing an antibiotic without a prescription. Enforcement includes regulations by law such as banning the dispensing of antibiotics in pharmacies without a prescription, compulsory generic substitution as well as national policies outlining the need for DTCs in hospitals and how their activities should be monitored.

14No ethical approval was required for this review as we were not dealing with patients. This is in line with previous similar papers published by the co-authors.

3. Results

15There are a number of key issues that need to be addressed to enhance appropriate antimicrobial use in patients and reduce AMR. We will break our findings down into key areas within hospitals and subsequently ambulatory care before concluding with guidance on potential activities that can be undertaken among all key stakeholder groups to reduce AMR.

16Activities that can be undertaken in hospitals include PPS studies to gain baseline data of current utilization patterns to guide future quality improvement programs as part of ASPs and other activities. Initiatives in ambulatory care center around activities to improve prescribing and dispensing of antimicrobials especially for self-limiting infections such as viral URTIs. These are especially important since, as mentioned, we are aware that up to 100% of pharmacies in LMICs dispense antibiotics without a prescription despite legislation, and this can account for up to 93% to 100% of all dispensed antibiotics. Having said this, HAIs are considered as the most adverse event in healthcare delivery.

3.1. Antimicrobial Use in Hospitals

17The first consideration within hospitals is to ensure that activities to improve antimicrobial prescribing are given a high priority if this is not already the case. This includes initiatives such as instigating active infection, prevention and control committees (IPC committees), which can be part of antimicrobial stewardship groups. The latter can be part of IPC committees or attached to Drug and Therapeutic Committees (DTCs). In addition, PPS studies can be undertaken and ASPs indicated to improve future antimicrobial use in hospitals (Table 1).

18However, there can be issues with the instigation of IPC committees and their effectiveness in hospitals (Table 1), concerns about the knowledge of ASPs among clinicians in LMICs, concerns with resource issues with establishing active ASPs including manpower, as well as a lack of institutional policies in LMICs. These issues can be exacerbated by a lack of clear commitment nationally despite the instigation of NAPs, which needs to be addressed to improve future antimicrobial use.

19Figure 1 incorporates the core elements of any ASP, with Kakkar et al. (2020) discussing the potential composition of personnel within antimicrobial stewardship groups in LMICs including physicians, pharmacists, microbiologists, infection control personnel as well as hospital administrators. Ideally, there should be a single focal point, with leaders of ASPs typically being either physicians or pharmacists, with pharmacists increasingly helping to drive forward ASPs in LMICs. ASPs can also be part of DTC activities if needed in some hospitals.

20Box 1 contains a number of indicators that have been used to assess the quality of antimicrobial prescribing within hospitals.

21Availability, ready access and subsequent compliance to local or regional treatment guidelines for key infections. This includes the availability of antibiograms within hospitals to guide empiric use whilst waiting for culture and sensitivity test (CST) findings as well as a potential list of restricted antibiotics depending on physician experienceWhether antibiotics prescribed are included in the hospital formulary/national essential medicine listsRationale (indication) for antimicrobial use documented in the patient’s notesWhether therapy was empiric or targeted based on CST findingsDocumentation of the dose in the patient’s notesDocumentation of a stop/review date for given antibiotics in the patient’s notes. This can include the rate of de-escalation to a narrower-spectrum antibiotic where appropriateDocumentation of any missed doses of antibioticsExtent of IV to oral switching (based on the stability of the gastrointestinal tract)Duration of surgical prophylaxisChanges in antibiotic use over time in terms of Defined Daily Doses/100(0) bed days and/or days of therapy/patient-daysWhether active antimicrobial stewardship groups and/or drug and therapeutic committees/Infection Prevention and Control groups in the hospital

22Availability, ready access and subsequent compliance to local or regional treatment guidelines for key infections. This includes the availability of antibiograms within hospitals to guide empiric use whilst waiting for culture and sensitivity test (CST) findings as well as a potential list of restricted antibiotics depending on physician experience

23Whether antibiotics prescribed are included in the hospital formulary/national essential medicine lists

24Rationale (indication) for antimicrobial use documented in the patient’s notes

25Whether therapy was empiric or targeted based on CST findings

26Documentation of the dose in the patient’s notes

27Documentation of a stop/review date for given antibiotics in the patient’s notes. This can include the rate of de-escalation to a narrower-spectrum antibiotic where appropriate

28Documentation of any missed doses of antibiotics

29Extent of IV to oral switching (based on the stability of the gastrointestinal tract)

30Duration of surgical prophylaxis

31Changes in antibiotic use over time in terms of Defined Daily Doses/100(0) bed days and/or days of therapy/patient-days

32Whether active antimicrobial stewardship groups and/or drug and therapeutic committees/Infection Prevention and Control groups in the hospital

33Multiple activities to reduce HAIs include encouraging greater hand hygiene, regular reviews surrounding the use and care of catheters, instigating appropriate strategies to reduce ventilator-associated pneumonia including subgluteal space suctioning before each position change, chlorhexidine gluconate bathing as well as active monitoring of agreed guidelines to reduce HAIs. A number of initiatives have been undertaken to improve hand hygiene in LMICs including those orchestrated by the WHO and others providing direction.

34Multiple activities can also be undertaken to improve antibiotic utilization to reduce SSIs among LMICs. Recent publications have documented that the number of patients receiving their first dose of antibiotics within 60 min of the first incision, with a second dose administered for longer procedures, can be as low as 6.7% of surgical patients in LMICs. This is a concern as studies have shown the risks of SSIs are almost five times higher when antibiotics are administered more than two hours prior to the first incision and almost doubled when administered after the first incision. There are also concerns that extending prophylaxis beyond one day, which is frequent among LMICs with for instance a mean up to 8.7 days post-operatively in Nigeria, does not appear to improve outcomes whilst concurrently increasing the potential for acute kidney injury, Clostridium difficile infections, and AMR as well as increasing costs. Vicentini et al. (2019) in their published study found that adequate antibiotic choices and length of administration were associated with significantly reduced risks of SSIs, with a number of approaches successfully undertaken in LMICs to improve antibiotic use surrounding the prevention of SSIs.

3.1.1. Antimicrobial Stewardship Programs (ASPs) and Other Activities to Improve Antimicrobial Utilization in Hospitals

35ASPs as well as other interventions can improve overall utilization of antimicrobials in hospitals as well as reduce costs alongwith improved hand hygiene and other activities to reduce HAIs and SSIs (Table 1). There are a number of areas that can be initial targets for ASP programs to gain their acceptance among key stakeholder groups in hospitals to address barriers. These include developing guidelines for specific indications and monitoring subsequent usage against these guidelines, as well as developing prompts for physicians to regularly review antibiotic prescriptions.

36Table 2 summarizes some of the activities that have been undertaken in LMICs to improve antimicrobial utilization in hospitals, which build on reviews in predominantly high-income countries including the use of computerized decision support systems. This includes (Table 2) activities surrounding SSIs and their impact to provide future guidance. Activities principally centre on educational initiatives, with educational initiatives known to enhance understanding of ASPs in LMICs given concerns about knowledge and activities among students and physicians in a number of LMICs.

37We are aware that ASPs have been successfully instigated in Accident and Emergency Departments in hospitals. However, this typically applies to higher-income countries.

3.1.2. Dealing with Antimicrobial Shortages in Hospitals

38Other strategies that antimicrobial stewardship groups and DTCs can undertake in hospitals is to develop effective approaches to address antimicrobial shortages, with medicine shortages being an increasing concern across countries. Shortages of antimicrobials can lead to administering less effective, more toxic, and costlier antimicrobials as well as potentially increasing AMR rates. One way to address this is for key personnel in hospitals, including those who are part of ASTs, to agree in advance therapeutic interchange strategies. This can include consultations between prescribers and hospital pharmacists before alternative antibiotics are administered.

39Emergency procurement procedures should also be in place in hospitals alongside regular reviews of stock levels in wards, exacerbated by the current COVID-19 pandemic. Available resources and funding is also essential to reduce the possibility of antimicrobial shortages in hospitals. The Bamako Initiative in sub-Saharan Africa is one such initiative adopted by Ministers of Health to increase access to medicines including antimicrobials through revolving drug funds. However, sustaining earlier gains with this initiative remains a challenge, and alternative drug financing schemes are essential to ensure physicians and patients can access appropriate antimicrobials in hospital to improve outcomes and reduce length of stay.

3.2. Antimicrobial Use in Ambulatory Care

40We will principally concentrate on ARIs as these are the most common infections seen in ambulatory care in LMICs and where the highest rate of inappropriate prescribing and dispensing takes place. Suboptimal management of ARIs in LMICs is exacerbated by a number of issues including social-cultural issues, diagnostic uncertainty, clinical competency and misconceptions as well as from commercial, patient and time pressures.

41Consequently, there are a number of strategies that can be undertaken in ambulatory care across LMICs to address current issues to improve future antimicrobial utilization. These can principally be divided into those impacting on the prescribing of antimicrobials by physicians for what are essentially viral infections, those strategies that can reduce inappropriate dispensing of antibiotics without a prescription as well as those that can address concerns with multi-resistant organisms for infections such as malaria and TB. In addition, there are a number of strategies that can be implemented to improve vaccination rates including during pandemics.

42Improving antimicrobial utilization in ambulatory care for ARIs is especially important in the current pandemic, with, as mentioned, published studies suggesting that over 70% of patients with COVID-19 are receiving antibiotics, including broad-spectrum antibiotics, even when not clinically indicated, with perhaps as low as 3.2% of infections in ambulatory care warranting antibiotics.

3.2.1. Initiatives among Physicians to Improve Antibiotic Prescribing

43A number of initiatives have been undertaken across LMICs to improve physician prescribing of antibiotics for ARIs. Table 3 summarizes examples of the many multiple activities that have been undertaken in LMICs to improve antimicrobial prescribing especially for ARIs, principally in education, and their impact.

44Among LMICs, there is an absolute imperative to develop actionable quality and patient safety indicators that better represent current prescribing compared with the traditional WHO/INRUD criteria. This reflects the rise in the number of patients in LMICs, especially sub-Saharan Africa, with both infectious and non-infectious communicable diseases (NCDs) as well as combinations of infectious diseases such as HIV and TB and combinations of infectious diseases and NCDs. Consequently, there is a need to develop more specific quality and patient safety indicators for LMICs to improve future antimicrobial prescribing. This can be achieved using agreed and common coding of data to enable coordinated and transferable learning between countries including patients attending ambulatory care clinics in sub-Saharan Africa. This will be the subject of future research activities among the group.

45These activities build on recent studies, including those undertaken in sub-Saharan Africa, suggesting that adherence to guidelines is a better indicator of the quality of prescribing in ambulatory care in LMICs compared with the current WHO/INRUD criteria. Having said that, it is important that there is only one national reference guideline since contradictions can arise when there are multiple guidelines within a country. It is also essential that any guidelines produced must be readily available in multiple media formats including online and downloadable, as well as in print. National guidelines also need to be combined with educational inputs and auditing of prescribing practices to further improve future prescribing.

46Regular updates of any guidelines, especially online, are also essential to improve adherence rates, and any updates need to be rapidly disseminated. This is being achieved among a number of sub-Saharan African countries through mobile technologies, providing guidance to other LMICs.

47We are aware though that over prescribing of antibiotics can be appreciably more common in telemedicine consultations than in face-to-face visits. Consequently, these consultations also need to be part of any future quality initiatives.

3.2.2. Initiatives to Reduce Inappropriate Dispensing of Antimicrobials among Pharmacists in the Community

48There are concerns with the extent of inappropriate dispensing of antimicrobials in community pharmacies and drugs stories across LMICs, especially with, as mentioned, such utilization accounting for up to 93% to 100% of all dispensed antibiotics.

49These concerns can be exacerbated by variable knowledge regarding antibiotics and AMR among community pharmacists. Having said this, there are key issues in rural settings in LMICs that need to be considered by Governments and others when reviewing strategies to reduce inappropriate dispensing of antimicrobials. These include the fact that pharmacists maybe the only healthcare professional available and they are trusted. There can also be major issues with affordability among patients in LMICs. Meeting both physician fees and the cost of medicines can have catastrophic consequences for individuals and families in LMICs. Trained pharmacists, assisted by guidelines, can reduce inappropriate self-purchasing of antibiotics in LMICs as well as be leaders of ambulatory care ASPs in their countries to improve future antibiotic utilization especially for infections that are essentially viral.

50Strategies to successfully reduce inappropriate self-purchasing of antimicrobials range from having well-educated pharmacists offering advice (Education) to patients as seen in Kenya, regulations by law restricting the purchasing of antimicrobials without a prescription coupled with fines (Economics and Enforcement), or a combination of these as seen in the Republic of Srpska (Education, Economics and Enforcement).

51The extent of ‘enforcement’ including the potential for fines or closure of pharmacies is vital as this impacts on the outcome of this intervention (Table 4). For instance, in Venezuela, the Government implemented policies to limit self-purchasing of antibiotics of three antibiotic groups. However, there were no public awareness campaigns and ‘Enforcement’ was only via government publications with no follow up. As a result, there was no decrease in antibiotic utilization levels but, in fact, the opposite with an increase. Similarly, in Colombia, whilst initial enforcement of the law in 2005 had a modest impact on overall sales in the first three years (−1.00 DDDs/1000 inhabitants per day), a follow-up study five years after implementation found that 80.3% of pharmacies were still not complying with the law due to lax monitoring, prompting calls for greater enforcement. This contrasts with an appreciable reduction in antibiotics dispensed without a prescription in a number of countries following multiple interventions, e.g., Saudi Arabia (Table 4).

52We see similar examples in other disease areas where the intensity of follow-up of prescribing restrictions (enforcement) appreciably impacts on their effectiveness and outcome in practice.

53However, it can be difficult in practice in a number of LMICs to enforce regulations banning self-purchasing of antibiotics due to manpower issues as well as shortages of antimicrobials within public healthcare facilities. Such activities may also be counter-productive in rural areas in LMICs and we have seen that trained pharmacists can help reduce inappropriate dispensing of antibiotics.

54Monitoring pharmacy dispensing activities through mobile technologies as well as potentially implementing information technology (IT) surveillance systems to track antibiotics through the supply chain are also potential strategies to reduce inappropriate dispensing.

55Adoption of such tactics may mean re-looking at pharmacists’ knowledge regarding AMR and its causes, with the potential for increased training if needed starting in pharmacy school and continuing post-qualification. In addition, potentially ensuring through regulation and other mechanisms that any antibiotic dispensed for ARIs and other common conditions are principally from the Access group of antibiotics and not from the WHO ‘Watch’ or ‘Reserve’ list.

3.2.3. Initiatives to Reduce Inappropriate Dispensing of Antimicrobials among Patients and the Public

56The impact of programs to reduce inappropriate prescribing and dispensing of antimicrobials for essentially viral infections such as ARIs can be enhanced by concurrently targeting patients and the public. This is because multiple studies have shown that some people can put considerable pressure on healthcare professionals to prescribe and dispense antibiotics for ARIs. Knowledge about antibiotics and AMR can vary though among patients and the public, and they can have strong beliefs about the effectiveness of antibiotics for them even for viral infections, which adds to the pressure to prescribe or dispense antimicrobials for ARIs.

57Similar to the situation with physicians and pharmacists, multifaceted approaches are needed to change attitudes and behaviors among patients and caregivers. However, such programs have had variable degrees of success for countries including both high-income countries and LMICs. Published studies, particularly among high-income countries, suggest that a number factors can enhance the success of any antibiotic awareness campaign. These include (i) the use of carefully designed simple key messages; (ii) targeting a wide audience including patients and their families; (iii) designing key messages for all key stakeholder groups for completeness; (iv) using mass media including social media to raise awareness; and (v) repeating key messages especially for new parents and others.

58Two systematic reviews have suggested that campaigns among patients can significantly reduce antibiotic utilization. McDonagh et al. (2018) found that parent education reduced antibiotic prescribing for ARIs by 21%. Cross et al. (2017), mainly including studies from high-income countries, also found that the majority of studies reported reductions in antibiotic utilization. The reduction was greater than 14% in the prescribing of antibiotics for RTIs, up to a maximum reduction of 30%.

59However, the impact of patient education initiatives in LMICs have not yet been fully elucidated, nor their costs and cost-effectiveness. Consequently, caution is still needed before fully embarking on such campaigns in LMICs unless these are part of research programs.

3.2.4. Initiatives to Address MDR Organisms for HIV, Malaria and TB

60There are concerns that patients with TB living in rural areas, and without regular supply of medicines, will have poorer treatment outcomes. Potential reasons for this include insufficient funds for transport to treatment centers despite the medicines often being provided free of charge alongwith missing out on regular reviews of medicine use addressing concerns including compliance with prescribed medicines, similar to the situation with NCDs. Poorer outcomes and lack of adherence to treatments will enhance resistance rates.

61The overall burden of TB has been declining at an annual average of 2%; however, the number of patients with drug-resistant TB (DR-TB) is increasing. Aminoglycosides, such as kanamycin, and some polypeptides, such as capreomycin, are used to treat DR-TB. However, whilst aminoglycosides are inhibitors of prokaryotic protein synthesis at commonly accepted therapeutic concentrations, they can affect the protein synthesis of cells at larger concentrations, leading to toxicity such as ototoxicity, vestibulotoxicity, and nephrotoxicity. Hearing loss though can now be monitored using an ototoxicity grading system within a mobile app to assist health professionals in assessing patients for ototoxicity. Subsequently, monitoring progression of hearing loss to improve planning for any changes in care. Such developments are likely to continue to improve the future use of aminoglycosides.

62There are also concerns with rising resistance rates to antimicrobials used to treat malaria since for instance when resistance of P. falciparum to sulfadoxine-pyrimethamine was greater than 10%, the risk ratio for malaria infections was 5.9 times higher compared to a period of time with low resistance rates, and the risk of death from malaria 10.8 times higher.

63Developing resistance to treatments for HIV also increases mortality with studies from sub-Saharan Africa indicating that when pre-treatment drug-resistance levels are evident but below 10%, AMR will be responsible for an estimated 710,000 AIDS deaths and 380,000 new infections by 2030. This increases to an estimated 890,000 AIDS deaths and 450,000 new infections by 2030 attributable to HIV when resistance rates are above 10%.

64Strategies to address concerns with resistance to treatments for HIV, malaria and TB include initiatives to ensure regular access to treatment facilities, including expanding these in rural areas given concerns with travel costs and time off work, as well as regular access to treatments ideally provided free of charge. Alongside this, regular monitoring of adherence rates knowing adherence can be a major issue in some patients. Strategies to improve adherence rates include patient and staff education addressing pertinent issues of anxiety and depression with their condition, encouraging clinic visits, addressing socioeconomic factors where possible as well as increasing the use of digital technologies including mobile phones and video-observed therapy.

65Concurrent with this, we are aware of groups in South Africa undertaking research on HIV reservoirs and using locally discovered potent, broadly neutralizing antibodies to neutralize HIV in the reservoir to render patients non-infectious as a cure strategy. Recent promising data from primates indicate the potential value of this approach and clinical trials are being planned.

66We are also aware of ongoing research that provides an expansive dataset of compounds that could be redirected for antimalarial development and also point towards proteins that can be targeted in multiple parasite life cycle stages to improve the management of patients with malaria resistant to current treatments. We will be monitoring these developments and their implications.

3.2.5. Programs to Address Concerns with Vaccine Uptake Including Misinformation as Well as Other Situations Adversely Affecting Antimicrobial Use

67Reduced vaccine uptake including vaccine hesitancy fueled by misinformation is a concern in view of the impact on AMR, morbidity and mortality (Table 5).

68This increasing recognition of the role of vaccines in reducing antimicrobial use and AMR is reflected in the recent WHO Action Framework to enhance current vaccination rates, encourage greater knowledge and dissemination on the role of vaccines to reduce AMR as well as encourage the development of new vaccines to further reduce AMR.

69Addressing mis- and dis-information surrounding vaccines is critical to reduce future morbidity and mortality arising from pandemics. We are already seeing social media companies such as Facebook and Twitter tightening up on accounts that repeatedly publish misinformation about COVID-19, building on activities among some African countries to fine companies for spreading misinformation, and such activities are likely to continue. This builds on activities by the WHO to join forces with Governments to address the level of misinformation surrounding COVID-19 as an example as well as Governments funding projects to specifically address misinformation surrounding vaccines for COVID-19 to enhance their uptake. Inclusivity is essential to engage with community groups and patient organizations, and ensure that clear public health messaging is delivered that is sensitive to age, culture, socioeconomic context and education, and to build population resilience against AMR behaviors.

70Potential ways forward, building on the activities of the WHO and Governments, especially with proposed medicines for COVID-19 including hydroxychloroquine, lopinavir/ritonavir and remdesivir that failed to live up to their preceived promise, include instigating a culture of evidence-based medicine among all key stakeholder groups starting in universities and continuing post-qualification. Such activities would have helped reduce shortages and price rises of hydroxychloroquine and antibiotics arising from the initial studies as well as help reduce inappropriate prescribing of antibiotics.

71Governments and others working with pertinent patient organizations within countries also need to proactively address misinformation, especially if, as mentioned, this increases future morbidity, mortality and costs, as seen with misinformation regarding hydroxychloroquine and unwarranted fears about vaccines. Transparent communication and appropriate public health messaging, in collaboration with patient groups and community leaders, are key for increasing the trust of the community and improving vaccination rates where concerns.

3.3. Suggested Activities among All Key Stakeholder Groups to Improve Future Antibiotic Utilization

72Suggested strategies to improve the utilization of antimicrobials among LMICs and thereby reduce AMR have been divided into short- and long-term initiatives to provide future guidance (Table 6). These build on the potential for expanding the use of electronic health records and electronic prescribing as well as digital technologies, including clinical decision support systems (CDSS), to improve appropriate use of antibiotics across countries and sectors in LMICs. Such developments should be welcomed given the increasing complexity of medical decision making and, as mentioned, the high percentage of patients especially in sub-Saharan Africa with co-morbidities including HIV, malaria and TB, as well as co-morbidities with both infectious and non-infectious diseases.

73Effectively addressing inappropriate antibiotic prescribing is particularly challenging since the majority of antibiotic prescribing in LMICs is undertaken by general clinicians and their assistants who are not experts in infection management and with often influence from pharmaceutical companies in the absence of continual professional development. This is compounded across Africa due to high workloads as well as limited consultation times and available resources, driven mainly by a shortage of healthcare professionals and the high prevalence of infectious diseases. Recent evidence is promising though about the feasibility and effectiveness of digital tools to improve future antibiotic prescribing and dispensing.

4. Discussion

74AMR continues to be a high priority across countries in view of its impact on morbidity, mortality and costs, driven by the overuse of antimicrobials across all sectors including in animals and for the treatment of infectious diseases in patients. The overuse of antimicrobials in humans has been exacerbated by the recent COVID-19 pandemic, where, as mentioned, typically less than 10% of COVID-19 patients have bacterial or fungal infections, with as low as 3.2% of COVID-19 infections warranting antibiotics. There are similar concerns with current low vaccination rates in a number of countries including current vaccine hesitancy surrounding the COVID-19 vaccine alongwith misinformation surrounding treatments for COVID-19, all of which negatively impact on costs and outcomes.

75Despite issues of resources including personnel, a number of activities can be undertaken in LMICs to improve future prescribing of antibiotics. These center around the instigation of ASPs in hospitals including PPS studies to identify areas for quality improvement, with a number of quality indicators now developed to monitor the appropriateness of future prescribing (Box 1). Strategies to improve future antibiotic prescribing in hospitals include those to reduce inappropriate timing and duration of antibiotic prescribing to prevent SSIs. Table 1 and Table 2 document a number of examples of initiatives that have been successfully instigated in hospitals in LMICs to improve future antibiotic prescribing, thereby providing exemplars to others.

76Successful strategies have also been implemented among physicians in LMIC to reduce inappropriate prescribing of antibiotics for essentially viral infections (Table 3), with patients playing a key role. Patients and pharmacists are also important to reduce inappropriate dispensing of antibiotics without a prescription (Table 4). However, recognizing that in rural LMICs, especially where there are high patient co-payment levels, community pharmacists maybe the only healthcare professional accessible and available. Community pharmacists are often more accessible than ambulatory care physicians in LMICs, and there is no need for physician co-pays, which combined with the cost of treatments can be catastrophic for some families.

77Healthcare professionals, including community pharmacists, along with patient organizations have a key role to play to encourage evidence-based approaches to healthcare, thereby reducing the impact of misinformation. Misinformation has been a real concern during the current COVID-19 pandemic resulting in for instance reduced uptake of the vaccines and the implications for this and other vaccines (Table 5), with a number of strategies identified to address this (Section 3.2.5).

78A number of strategies and initiatives have also been identified to reduce levels of multi-drug resistance organisms to HIV, malaria, and TB, given the resultant impact on morbidity and mortality. Key areas include the provision of treatments free of charge, ready access to healthcare facilities as well as initiatives to enhance adherence to prescribed treatments.

79Potential strategies for all key stakeholders were subsequently consolidated into short-, medium- and long-term activities to provide future direction (Table 6). The key is Government commitment through NAPs and other activities to drive forward future initiatives. We will be monitoring the situation given continued concerns with AMR and its resultant impact on mortality as well as GDP.

80We are aware of a number of limitations with this review paper. These include the fact that we did not undertake a systematic review for the reasons discussed. We also did not break the number of examples down by country or care setting as our objective was to provide pertinent examples to guide others. In addition, we are aware that some developing countries are more pro-active with their research than others, potentially biasing the findings. Despite these limitations, we believe that our findings and suggestions are robust, providing future direction.

5. Conclusions

81In conclusion, reducing AMR should be a high priority across countries given its clinical and economic impact. Reducing AMR rates requires multiple coordinated activities across sectors driven by Governments and others. This is essential given limited new antimicrobials being developed, although compensated to some extent by developments in vaccine technologies. This will also require strategies to address high rates of vaccine hesitance that exist in a number of countries as seen in the recent COVID-19 pandemic. A coordinated approach including all key stakeholder groups is also essential to minimize misinformation and maximize the impact of future interventions to reduce AMR rates.

References 394

1.
Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis · 2019
No notice
2.
Hofer U. The cost of antimicrobial resistance. Nat. Rev. Genet. 2019;17:3.
Not in our library10.1038/s41579-018-0125-x
3.
Majumder M.A., Rahman S., Cohall D., Bharatha A., Singh K., Haque M., Gittens-St Hilaire M. Antimicrobial Stewardship: Fighting Antimicrobial Resistance and Protecting Global Public Health. Infect. Drug Resist. 2020;13:4713-4738.
Not in our library10.2147/idr.s290835
4.
Clinical and economic impact of antibiotic resistance in developing countries: A systematic review and meta-analysis · 2017
No notice
5.
Ndir A., Diop A., Ka R., Faye P.M., Dia-Badiane N.M., Ndoye B., Astagneau P. Infections caused by extended-spectrum beta-lactamases producing Enterobacteriaceae: Clinical and economic impact in patients hospitalized in 2 teaching hospitals in Dakar, Senegal. Antimicrob. Resist. Infect. Control. 2016;5:13.
Not in our library10.1186/s13756-016-0114-7
6.
Jiang T., Chen X.S. Outcome Impacts due to Pathogen-Specific Antimicrobial Resistance: A Narrative Review of Published Literature. Int. J. Environ. Res. Public Health. 2020;17:1395.
Not in our library10.3390/ijerph17041395
7.
Graham W.J., Morrison E., Dancer S., Afsana K., Aulakh A., Campbell O.M., Cross S., Ellis R., Enkubahiri S., Fekad B., et al. What are the threats from antimicrobial resistance for maternity units in low- and middle-income countries? Glob. Health Action. 2016;9:33381.
Not in our library10.3402/gha.v9.33381
8.
KPMG. The Global Economic Impact of Anti-Microbial Resistance.
Not in our library
9.
Yusuf M.A. Antimicrobial Stewardship: Bangladesh Perspective. Bangladesh J. Infect. Dis. 2018;5:1-2.
Not in our library10.3329/bjid.v5i1.37708
10.
Jansen K.U., Anderson A.S. The role of vaccines in fighting antimicrobial resistance (AMR). Hum. Vaccines Immunother. 2018;14:2142-2149.
Not in our library10.1080/21645515.2018.1476814
11.
O’Neill. Tackling Drug-resistant Infections Globally: Final Report and Recommendations.
Not in our library
12.
OECD Health Policy Studies, Stemming the Superbug Tide.
Not in our library
13.
Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use · 2018
No notice
14.
Haque M., Godman B. Potential Strategies to Improve Antimicrobial Utilisation in Hospitals in Bangladesh Building on Experiences Across Developing Countries. Bangladesh J. Med. Sci. 2021;19:355-357.
Not in our library10.3329/bjms.v19i3.45849
15.
IACG. No Time to Wait: Securing the Future from Drug-Resistant Infections. Report to the Sec-Retary-General of the United Nations. April.
Not in our library
16.
Urmi U.L., Nahar S., Rana M., Sultana F., Jahan N., Hossain B., Alam M.S., Mosaddek A.S., McKimm J., Rahman N.A., et al. Genotypic to Phenotypic Resistance Discrepancies Identified Involving β-Lactamase Genes, blaKPC, blaIMP, blaNDM-1, and blaVIM in Uropathogenic Klebsiella pneumoniae. Infect. Drug Resist. 2020;13:2863-2875.
Not in our library10.2147/idr.s262493
17.
Ara B., Urmi U.L., Haque T.A., Nahar S., Rumnaz A., Ali T., Alam M.S., Mosaddek A.S.M., A Rahman N.A., Haque M., et al. Detection of mobile colistin-resistance gene variants (mcr-1 and mcr-2) in urinary tract pathogens in Bangladesh: The last resort of infectious disease management colistin efficacy is under threat. Expert Rev. Clin. Pharm. 2021;14:513-522.
Not in our library10.1080/17512433.2021.1901577
18.
Antibiotic resistance in Bangladesh: A systematic review · 2019
Not checked
19.
The World Bank. Final Report—Drug-Resistant Infections. A Threat to Our Economic Future.
Not in our library
20.
Global increase and geographic convergence in antibiotic consumption between 2000 and 2015 · 2018
No notice
21.
Sriram A., Kalanxhi E., Kapoor G., Craig J., Balasubramanian R., Brar S., Criscuolo N., Hamilton A., Klein E., Tseng K., et al. State of the World’s Antibiotics 2021: A Global Analysis of Antimicrobial Resistance and Its Drivers.
Not in our library
22.
Llor C., Bjerrum L. Antimicrobial resistance: Risk associated with antibiotic overuse and initiatives to reduce the problem. Adv. Drug Saf. 2014;5:229-241.
Not in our library10.1177/2042098614554919
23.
Morel C.M., Alm R.A., Årdal C., Bandera A., Bruno G.M., Carrara E., Colombo G.L., de Kraker M.E., Essack S., Frost I., et al. A one health framework to estimate the cost of anti-microbial resistance. Antimicrob. Resist. Infect. Control. 2020;9:187.
Not in our library10.1186/s13756-020-00822-6
24.
The threat of antimicrobial resistance in developing countries: causes and control strategies · 2017
No notice
25.
Dadgostar P. Antimicrobial Resistance: Implications and Costs. Infect. Drug Resist. 2019;12:3903-3910.
Not in our library10.2147/idr.s234610
26.
Khan J.Z., Hassan Z., Tajik M.I. Antibiotic Resistance: Recommendations for Procurement Agencies of Public Sector Hospitals in Pakistan. J. Coll. Physicians Surg. Pak. 2020;30:340-341.
Not in our library10.29271/jcpsp.2020.03.340
27.
Mohsin M., Van Boeckel T.P., Saleemi M.K., Umair M., Naseem M.N., He C., Khan A., Laxminarayan R. Excessive use of medically important antimicrobials in food animals in Pakistan: A five-year surveillance survey. Glob. Health Action. 2019;12(Suppl. 1):1697541.
Not in our library10.1080/16549716.2019.1697541
28.
Ali M., Irtiqa A., Mahrukh F., Tooba A. Factors leading to acquired bacterial resistance due to antibiotics in Pakistan. Curr. Trends Biotechnol. Microbiol. 2018;1:1-7.
Not in our library10.32474/ctbm.2018.01.000101
29.
Bokhary H., Pangesti K., Rashid H., El Ghany M.A., Hill-Cawthorne G. Travel-Related Antimicrobial Resistance: A Systematic Review. Trop. Med. Infect. Dis. 2021;6:11.
Not in our library10.3390/tropicalmed6010011
30.
Hoque R., Ahmed S.M., Naher N., Islam M.A., Rousham E.K., Islam B.Z., Hassan S. Tackling antimicrobial resistance in Bangladesh: A scoping review of policy and practice in human, animal and environment sectors. PLoS ONE. 2020;15:e0227947.
Not in our library10.1371/journal.pone.0227947
31.
Islam M.A., Islam M., Hasan R., Hossain M.I., Nabi A., Rahman M., Goessens W.H., Endtz H.P., Boehm A.B., Faruque S.M. Environmental Spread of New Delhi Metal-lo-β-Lactamase-1-Producing Multidrug-Resistant Bacteria in Dhaka, Bangladesh. Appl. Environ. Microbiol. 2017;83:e00793-17.
Not in our library10.1128/aem.00793-17
32.
Buchy P., Ascioglu S., Buisson Y., Datta S., Nissen M., Tambyah P.A., Vong S. Impact of vaccines on antimicrobial resistance. Int. J. Infect. Dis. 2020;90:188-196.
Not in our library10.1016/j.ijid.2019.10.005
33.
Evaluating antimicrobial resistance in the global shrimp industry · 2019
No notice
34.
Aworh M.K., Kwaga J., Okolocha E., Harden L., Hull D., Hendriksen R.S., Thakur S. Extended-spectrum ß-lactamase-producing Escherichia coli among humans, chickens and poultry environments in Abuja, Nigeria. One Health Outlook. 2020;2:8.
Not in our library10.1186/s42522-020-00014-7
35.
Van Boeckel T.P., Pires J., Silvester R., Zhao C., Song J., Criscuolo N.G., Gilbert M., Bonhoeffer S., Laxminarayan R. Global trends in antimicrobial resistance in animals in low- and middle-income countries. Science. 2019;365:1251.
Not in our library10.1126/science.aaw1944
36.
Response to the Novel Corona Virus (COVID-19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future · 2020
No notice
37.
Routine childhood immunisation during the COVID-19 pandemic in Africa: a benefit–risk analysis of health benefits versus excess risk of SARS-CoV-2 infection · 2020
Corrected
38.
Olorunsaiye C.Z., Yusuf K.K., Reinhart K., Salihu H.M. COVID-19 and Child Vaccination: A Systematic Approach to Closing the Immunization Gap. Int. J. Matern. Child Health AIDS. 2020;9:381-385.
Not in our library10.21106/ijma.401
39.
WHO. At Least 80 Million Children under One at Risk of Diseases such as Diphtheria, Measles and Polio as COVID-19 Disrupts Routine Vaccination Efforts, Warn Gavi, WHO and UNICEF.
Not in our library
40.
Atkins K.E., Flasche S. Vaccination to reduce antimicrobial resistance. Lancet Glob. Health. 2018;6:e252.
Not in our library10.1016/s2214-109x(18)30043-3
41.
Rodríguez-Álvarez M., López-Vidal Y., Soto-Hernández J.L., Miranda-Novales M.G., Flores-Moreno K., de León-Rosales S.P. COVID-19: Clouds Over the Antimicrobial Resistance Landscape. Arch. Med. Res. 2021;52:123-126.
Not in our library10.1016/j.arcmed.2020.10.010
42.
Troisi M., Andreano E., Sala C., Kabanova A., Rappuoli R. Vaccines as remedy for antimicrobial resistance and emerging infections. Curr. Opin. Immunol. 2020;65:102-106.
Not in our library10.1016/j.coi.2020.09.003
43.
Wilson S.L., Wiysonge C. Social media and vaccine hesitancy. BMJ Glob. Health. 2020;5:e004206.
Not in our library10.1136/bmjgh-2020-004206
44.
Piedrahita-Valdés H., Piedrahita-Castillo D., Bermejo-Higuera J., Guillem-Saiz P., Bermejo-Higuera J.R., Guillem-Saiz J., Sicilia-Montalvo J.A., Machío-Regidor F. Vaccine Hesitancy on Social Media: Sentiment Analysis from June 2011 to April 2019. Vaccines. 2021;9:28.
Not in our library10.3390/vaccines9010028
45.
Jarchow-MacDonald A.A., Burns R., Miller J., Kerr L., Willocks L.J. Keeping childhood immunisation rates stable during the COVID-19 pandemic. Lancet Infect. Dis. 2021;21:459-460.
Not in our library10.1016/s1473-3099(20)30991-9
46.
UNA-SUS. FIOCRUZ IN THE AIR: Covid-19 and Antibiotic Self-Medication: A Dangerous Combination.
Not in our library
47.
Schueler P. Antibiotic Resistance and COVID-19.
Not in our library
48.
Iwu C.J., Jordan P., Jaja I.F., Iwu C.D., Wiysonge C.S. Treatment of COVID-19: Implications for antimicrobial resistance in Africa. Pan Afr. Med. J. 2020;35.
Not in our library10.11604/pamj.supp.2020.35.2.23713
49.
Sefah I.A., Ogunleye O.O., Essah D.O., Opanga S.A., Butt N., Wamaitha A., Guantai A.N., Chikowe I., Khuluza F., Kibuule D., et al. Rapid Assessment of the Potential Paucity and Price Increases for Suggested Medicines and Protection Equipment for COVID-19 across Developing Countries with a Particular Focus on Africa and the Implications. Front. Pharm. 2021;11:588106.
Not in our library10.3389/fphar.2020.588106
50.
Ongole J.J., Rossouw T.M., Fourie P.B., Stoltz A.C., Hugo J., Marcus T.S. Sustaining essential healthcare in Africa during the COVID-19 pandemic. Int. J. Tuberc. Lung Dis. 2020;24:643-645.
Not in our library10.5588/ijtld.20.0214
51.
Strathdee S.A., Davies S.C., Marcelin J.R. Confronting antimicrobial resistance beyond the COVID-19 pandemic and the 2020 US election. Lancet. 2020;396:1050-1053.
Not in our library10.1016/s0140-6736(20)32063-8
52.
Rawson T.M., Moore L.S.P., Zhu N., Ranganathan N., Skolimowska K., Gilchrist M., Satta G., Cooke G., Holmes A. Bacterial and Fungal Coinfection in Individuals with Coronavirus: A Rapid Review to Support COVID-19 Antimicrobial Prescribing. Clin. Infect. Dis. 2020;71:2459-2468.
Not in our library10.1093/cid/ciaa530
53.
Hsu J. How covid-19 is accelerating the threat of antimicrobial resistance. BMJ. 2020;369:m1983.
Not in our library10.1136/bmj.m1983
54.
Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge · 2020
No notice
55.
Langford B.J., So M., Raybardhan S., Leung V., Soucy J.-P.R., Westwood D., Daneman N., MacFadden D.R. Antibiotic prescribing in patients with COVID-19: Rapid review and meta-analysis. Clin. Microbiol. Infect. 2021;27:520-531.
Not in our library10.1016/j.cmi.2020.12.018
56.
Interagency Coordination Group on Antimicrobial Resistance. No Time to Wait: Securing the Future from Drug-Resistant Infections-Report to the Secretary-General of the United Nations. 2019.
Not in our library
57.
World Health Organisation. Antimicrobial Resistance. 2018.
Not in our library
58.
WHO. The Role of Pharmacist in Encouraging Prudent Use of Antibiotics and Averting Antimicrobial Resistance: A Review of Policy and Experience. 2014.
Not in our library
59.
Federal Ministries of Agriculture, Rural Development, Environment and Health, Abuja, Nigeria. National Action Plan for Antimicrobial Resistance, 2017–2022.
Not in our library
60.
Saleem Z., Hassali M.A., Hashmi F.K. Pakistan’s national action plan for antimicrobial resistance: Translating ideas into reality. Lancet Infect. Dis. 2018;18:1066-1067.
Not in our library10.1016/s1473-3099(18)30516-4
61.
Fürst J., Čižman M., Mrak J., Kos D., Campbell S., Coenen S., Gustafsson L.L., Fürst L., Godman B. The influence of a sustained multifaceted approach to improve antibiotic prescribing in Slovenia during the past decade: Findings and implications. Expert Rev. Anti-Infect. Ther. 2014;13:279-289.
Not in our library10.1586/14787210.2015.990381
62.
Abilova V., Kurdi A., Godman B. Ongoing initiatives in Azerbaijan to improve the use of antibiotics; findings and implications. Expert Rev. Anti-Infect. Ther. 2018;16:77-84.
Not in our library10.1080/14787210.2018.1417835
63.
Engler D., Meyer J.C., Schellack N., Kurdi A., Godman B. Compliance with South Africa’s Antimicrobial Resistance National Strategy Framework: Are we there yet? J. Chemother. 2021;33:21-31.
Not in our library10.1080/1120009x.2020.1789389
64.
Godman B., Haque M., McKimm J., Abu Bakar M., Sneddon J., Wale J., Campbell S., Martin A., Hoxha I., Abilova V., et al. Ongoing strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle-income countries: Findings and implications for the future. Curr. Med. Res. Opin. 2019;36:301-327.
Not in our library10.1080/03007995.2019.1700947
65.
Government of India. National Action Plan Antimicrobial Resistance (NAP-AMR) 2017–2021.
Not in our library
66.
Significant reduction of antibiotic consumption and patients' costs after an action plan in China, 2010-2014. · 2015
Not checked
67.
Versporten A., Bolokhovets G., Ghazaryan L., Abilova V., Pyshnik G., Spasojevic T., Korinteli I., Raka L., Kambaralieva B., Cizmovic L., et al. Antibiotic use in eastern Europe: A cross-national database study in coordination with the WHO Regional Office for Europe. Lancet Infect. Dis. 2014;14:381-387.
Not in our library10.1016/s1473-3099(14)70071-4
68.
Brazilian Health Regulatory Agency. National Program for the Prevention and Control of Healthcare Associated Infections (2016–2020).
Not in our library
69.
WHO. Global Action Plan on Antimicrobial Resistance. 2015.
Not in our library
70.
Ghana Ministry of Health, Ministry of Food and Agriculture, Ministry of Environment, Science, Technology and Innovation, Ministry of Fisheries and Aquaculture Development. Ghana National Action Plan for Antimicrobial Use and Resistance. 2017–2021.
Not in our library
71.
Mendelson M., Matsoso M.P. The South African Antimicrobial Resistance Strategy Framework. AMR Control. 2015;54-61.
Not in our library
72.
Republic of Kenya. National Action Plan on Prevention and Containment of Antimicrobial Re-Sistance, 2017–2022.
Not in our library
73.
Ministry of Health and Family Welfare (MoHFW), Government of Bangladesh. National Action Plan: Antimicrobial Resistance Containment in Bangladesh 2017-’22.
Not in our library
74.
Munkholm L., Rubin O. The global governance of antimicrobial resistance: A cross-country study of alignment between the global action plan and national action plans. Glob. Health. 2020;16:109.
Not in our library10.1186/s12992-020-00639-3
75.
Zaney G.D. Ghana’s National Action Plan on AMR Implementation on Course—But It Requires Support from All.
Not in our library
76.
Sangeda R.Z., Kibona J., Munishi C., Arabi F., Manyanga V.P., Mwambete K.D., Horumpende P.G. Assessment of Implementation of Antimicrobial Resistance Surveillance and Antimicrobial Stewardship Programs in Tanzanian Health Facilities a Year after Launch of the National Action Plan. Front. Public Health. 2020;8:454.
Not in our library10.3389/fpubh.2020.00454
77.
Determinants of mortality among patients with drug-resistant tuberculosis in northern Nigeria. · 2019
Not checked
78.
Akram J., Khan A.S., Khan H.A., Gilani S.A., Akram S.J., Ahmad F.J., Mehboob R. Extensively Drug-Resistant (XDR) Typhoid: Evolution, Prevention, and Its Management. BioMed Res. Int. 2020;2020:6432580.
Not in our library10.1155/2020/6432580
79.
Kurbatova E.V., Taylor A., Gammino V.M., Bayona J., Becerra M., Danilovitz M., Falzon D., Gelmanova I., Keshavjee S., Leimane V., et al. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis. 2012;92:397-403.
Not in our library10.1016/j.tube.2012.06.003
80.
Ali M.H., Alrasheedy A.A., Kibuule D., Godman B., Hassali M.A., Ali H.M.H. Assessment of multidrug-resistant tuberculosis (MDR-TB) treatment outcomes in Sudan; findings and implications. Expert Rev. Anti-Infect. Ther. 2019;17:927-937.
Not in our library10.1080/14787210.2019.1689818
81.
Bojanić L., Markovic-Pekovic V., Skrbic R., Stojakovic N., Ðermanović M., Bojanić J., Fürst J., Kurdi A.B., Godman B. Recent Initiatives in the Republic of Srpska to Enhance Appropriate Use of Antibiotics in Ambulatory Care; Their Influence and Implications. Front. Pharm. 2018;9.
Not in our library10.3389/fphar.2018.00442
82.
Wojkowska-Mach J., Godman B., Glassman A., Kurdi A., Pilc A., Rozanska A., Skoczyński S., Wałaszek M., Bochenek T. Antibiotic consumption and antimicrobial resistance in Poland; findings and implications. Antimicrob. Resist. Infect. Control. 2018;7:136.
Not in our library10.1186/s13756-018-0428-8
83.
Saleem Z., Hassali M.A., Godman B., Hashmi F.K., Saleem F. A multicenter point prevalence survey of healthcare-associated infections in Pakistan: Findings and implications. Am. J. Infect. Control. 2019;47:421-424.
Not in our library10.1016/j.ajic.2018.09.025
84.
Mwita J.C., Ogunleye O.O., Olalekan A., Kalungia A.C., Kurdi A., Saleem Z., Sneddon J., Godman B. Key Issues Surrounding Appropriate Antibiotic Use for Prevention of Surgical Site Infections in Low- and Middle-Income Countries: A Narrative Review and the Implications. Int. J. Gen. Med. 2021;14:515-530.
Not in our library10.2147/ijgm.s253216
85.
Haque M., McKimm J., Godman B., Abu Bakar M., Sartelli M. Initiatives to reduce postoperative surgical site infections of the head and neck cancer surgery with a special emphasis on developing countries. Expert Rev. Anticancer. Ther. 2018;19:81-92.
Not in our library10.1080/14737140.2019.1544497
86.
Value of hospital antimicrobial stewardship programs [ASPs]: a systematic review · 2019
No notice
87.
Akpan M.R., Isemin N.U., Udoh A.E., Ashiru-Oredope D. Implementation of antimicrobial stewardship programmes in African countries: A systematic literature review. J. Glob. Antimicrob. Resist. 2020;22:317-324.
Not in our library10.1016/j.jgar.2020.03.009
88.
Anand Paramadhas B.D., Tiroyakgosi C., Mpinda-Joseph P., Morokotso M., Matome M., Sinkala F., Gaolebe M., Malone B., Molosiwa E., Shanmugam M.G., et al. Point prevalence study of antimicrobial use among hospitals across Botswana; findings and implications. Expert Rev. Anti-Infect. Ther. 2019;17:535-546.
Not in our library10.1080/14787210.2019.1629288
89.
Cai Y., Shek P.Y., Teo I., Tang S.S., Lee W., Liew Y.X., Chlebicki P., Kwa A.L. A multidisciplinary antimicrobial stewardship programme safely decreases the duration of broad-spectrum antibiotic prescription in Singaporean adult renal patients. Int. J. Antimicrob. Agents. 2016;47:91-96.
Not in our library10.1016/j.ijantimicag.2015.10.021
90.
Tang S.J., Gupta R., Lee J.I., Majid A.M., Patel P., Efird L., Loo A., Mazur S., Calfee D.P., Archambault A., et al. Impact of Hospitalist-Led Interdisciplinary Antimicrobial Stewardship Interventions at an Academic Medical Center. Jt. Comm. J. Qual. Patient Saf. 2019;45:207-216.
Not in our library10.1016/j.jcjq.2018.09.002
91.
Schuts E.C., Hulscher M., Mouton J.W., Verduin C.M., Stuart J., Overdiek H., van der Linden P.D., Natsch S., Hertogh C.M.P.M., Wolfs T.F.W., et al. Current evidence on hospital antimicrobial stewardship objectives: A systematic review and meta-analysis. Lancet Infect. Dis. 2016;16:847-856.
Not in our library10.1016/s1473-3099(16)00065-7
92.
Shirazi O.U., Ab Rahman N.S., Zin C.S. A Narrative Review of Antimicrobial Stewardship Interventions within In-Patient Settings and Resultant Patient Outcomes. J. Pharm. Bioallied. Sci. 2020;12:369-380.
Not in our library10.4103/jpbs.jpbs_311_19
93.
Satterfield J., Miesner A.R., Percival K.M. The role of education in antimicrobial stewardship. J. Hosp. Infect. 2020;105:130-141.
Not in our library10.1016/j.jhin.2020.03.028
94.
Seni J., Mapunjo S.G., Wittenauer R., Valimba R., Stergachis A., Werth B.J., Saitoti S., Mhadu N.H., Lusaya E., Konduri N. Antimicrobial use across six referral hospitals in Tanzania: A point prevalence survey. BMJ Open. 2020;10:e042819.
Not in our library10.1136/bmjopen-2020-042819
95.
Álvarez-Marín R., López-Cerero L., Guerrero-Sánchez F., Palop-Borras B., Rojo-Martín M.D., Ruiz-Sancho A., Herrero-Rodríguez C., García M.V., Lazo-Torres A.M., López I., et al. Do specific antimicrobial stewardship interventions have an impact on carbapenem resistance in Gram-negative bacilli? A multicentre quasi-experimental ecological study: Time-trend analysis and characterization of carbapenemases. J. Antimicrob. Chemother. 2021.
Not in our library10.1093/jac/dkab073
96.
López-Viñau T., Peñalva G., García-Martínez L., Castón J.J., Muñoz-Rosa M., Cano Á., Recio M., Cisneros J.M., Pérez-Nadales E., Rumbao Aguirre J., et al. Impact of an Antimicrobial Stewardship Program on the Incidence of Carbapenem Resistant Gram-Negative Bacilli: An Interrupted Time-Series Analysis. Antibiotics. 2021;10:586.
Not in our library10.3390/antibiotics10050586
97.
Cox J.A., Vlieghe E., Mendelson M., Wertheim H., Ndegwa L., Villegas M.V., Gould I., Hara G.L. Antibiotic stewardship in low- and middle-income countries: The same but different? Clin. Microbiol. Infect. 2017;23:812-818.
Not in our library10.1016/j.cmi.2017.07.010
98.
Brink A.J., Messina A.P., Feldman C., Richards G.A., Becker P.J., Goff D.A., Bauer K.A., Nathwani D., Bergh D.V.D. Antimicrobial stewardship across 47 South African hospitals: An implementation study. Lancet Infect. Dis. 2016;16:1017-1025.
Not in our library10.1016/s1473-3099(16)30012-3
99.
Mukokinya M.M.A., Opanga S., Oluka M., Godman B. Dispensing of antimicrobials in Kenya: A cross-sectional pilot study and its implications. J. Res. Pharm. Pract. 2018;7:77.
Not in our library10.4103/jrpp.jrpp_17_88
100.
Assessing the impact of law enforcement to reduce over-the-counter (OTC) sales of antibiotics in low- and middle-income countries; a systematic literature review · 2019
Not checked
101.
Olaoye O., Tuck C., Khor W.P., McMenamin R., Hudson L., Northall M., Panford-Quainoo E., Asima D.M., Ashiru-Oredope D. Improving Access to Antimicrobial Prescribing Guidelines in 4 African Countries: Development and Pilot Implementation of an App and Cross-Sectional Assessment of Attitudes and Behaviour Survey of Healthcare Workers and Patients. Antibiotics. 2020;9:555.
Not in our library10.3390/antibiotics9090555
102.
Gasson J., Blockman M., Willems B. Antibiotic prescribing practice and adherence to guidelines in primary care in the Cape Town Metro District, South Africa. S. Afr. Med. J. 2018;108:304-310.
Not in our library10.7196/samj.2018.v108i4.12564
103.
Elias C., Moja L., Mertz D., Loeb M., Forte G., Magrini N. Guideline recommendations and antimicrobial resistance: The need for a change. BMJ Open. 2017;7:e016264.
Not in our library10.1136/bmjopen-2017-016264
104.
Saleem Z., Godman B., Hassali M.A., Hashmi F.K., Azhar F., Rehman I.U. Point prevalence surveys of health-care-associated infections: A systematic review. Pathog. Glob. Health. 2019;113:191-205.
Not in our library10.1080/20477724.2019.1632070
105.
Saleem Z., Hassali M.A., Godman B., Versporten A., Hashmi F.K., Saeed H., Saleem F., Salman M., Rehman I.U., Khan T.M. Point prevalence surveys of antimicrobial use: A systematic review and the implications. Expert Rev. Anti-Infect. Ther. 2020;18:897-910.
Not in our library10.1080/14787210.2020.1767593
106.
Rappuoli R., De Gregorio E., Del Giudice G., Phogat S., Pecetta S., Pizza M., Hanon E. Vaccinology in the post-COVID-19 era. Proc. Natl. Acad. Sci. USA. 2021;118:e2020368118.
Not in our library10.1073/pnas.2020368118
107.
Batura N., Cuevas C., Khan M., Wiseman V. How effective and cost-effective are behaviour change interventions in improving the prescription and use of antibiotics in low-income and middle-income countries? A protocol for a systematic review. BMJ Open. 2018;8:e021517.
Not in our library10.1136/bmjopen-2018-021517
108.
Cooper L., Sneddon J., Afriyie D.K., Sefah I.A., Kurdi A., Godman B., Seaton R.A. Supporting global antimicrobial stewardship: Antibiotic prophylaxis for the prevention of surgical site infection in low- and middle-income countries (LMICs): A scoping review and meta-analysis. JAC-Antimicrob. Resist. 2020;2.
Not in our library10.1093/jacamr/dlaa070
109.
Household antimicrobial self-medication: a systematic review and meta-analysis of the burden, risk factors and outcomes in developing countries · 2015
No notice
110.
da Silva A.A., de Almeida Dias D.A., Marques A.F., di Biase C.B., Murni I.K., Dramowski A., Sharland M., Huebner J., Zingg W. Role of antimicrobial stewardship programmes in children: A systematic review. J. Hosp. Infect. 2018;99:117-123.
Not in our library10.1016/j.jhin.2017.08.003
111.
Huebner C., Flessa S., Huebner N.O. The economic impact of antimicrobial stewardship programmes in hospitals: A systematic literature review. J. Hosp. Infect. 2019;102:369-376.
Not in our library10.1016/j.jhin.2019.03.002
112.
Karanika S., Paudel S., Grigoras C., Kalbasi A., Mylonakis E. Systematic Review and Meta-analysis of Clinical and Economic Outcomes from the Implementation of Hospital-Based Antimicrobial Stewardship Programs. Antimicrob. Agents Chemother. 2016;60:4840-4852.
Not in our library10.1128/aac.00825-16
113.
Holloway K.A., Rosella L., Henry D. The Impact of WHO Essential Medicines Policies on Inappropriate Use of Antibiotics. PLoS ONE. 2016;11:e0152020.
Not in our library10.1371/journal.pone.0152020
114.
Md Rezal R.S., Hassali M.A., Alrasheedy A.A., Saleem F., Md Yusof F.A., Godman B. Physicians’ knowledge, perceptions and behaviour towards antibiotic prescribing: A systematic review of the literature. Expert Rev. Anti-Infect. Ther. 2015;13:665-680.
Not in our library10.1586/14787210.2015.1025057
115.
Dar O.A., Hasan R., Schlundt J., Harbarth S., Caleo G., Dar F.K., Littmann J., Rweyemamu M., Buckley E.J., Shahid M., et al. Exploring the evidence base for national and regional policy interventions to combat resistance. Lancet. 2016;387:285-295.
Not in our library10.1016/s0140-6736(15)00520-6
116.
McDonagh M.S., Peterson K., Winthrop K., Cantor A., Lazur B.H., Buckley D.I. Interventions to reduce inappropriate prescribing of antibiotics for acute respiratory tract infections: Summary and update of a systematic review. J. Int. Med. Res. 2018;46:3337-3357.
Not in our library10.1177/0300060518782519
117.
Dyar O.J., Beovic B., Vlahovic-Palcevski V., Verheij T., Pulcini C. How can we improve antibiotic prescribing in primary care? Expert Rev. Anti-Infect. Ther. 2016;14:403-413.
Not in our library10.1586/14787210.2016.1151353
118.
Auta A., Hadi M.A., Oga E., Adewuyi E.O., Abdu-Aguye S.N., Adeloye D., Strickland-Hodge B., Morgan D.J. Global access to antibiotics without prescription in community pharmacies: A systematic review and meta-analysis. J. Infect. 2019;78:8-18.
Not in our library10.1016/j.jinf.2018.07.001
119.
Köchling A., Löffler C., Reinsch S., Hornung A., Böhmer F., Altiner A., Chenot J.F. Reduction of antibiotic prescriptions for acute respiratory tract infections in primary care: A systematic review. Implement. Sci. 2018;13:47.
Not in our library10.1186/s13012-018-0732-y
120.
McKay R., Mah A., Law M.R., McGrail K., Patrick D.M. Systematic Review of Factors Associated with Antibiotic Prescribing for Respiratory Tract Infections. Antimicrob. Agents Chemother. 2016;60:4106-4118.
Not in our library10.1128/aac.00209-16
121.
Educational interventions to improve prescription and dispensing of antibiotics: a systematic review · 2014
No notice
122.
Teixeira Rodrigues A., Roque F., Falcao A., Figueiras A., Herdeiro M.T. Understanding physician antibiotic prescribing behaviour: A systematic review of qualitative studies. Int. J. Antimicrob. Agents. 2013;41:203-212.
Not in our library10.1016/j.ijantimicag.2012.09.003
123.
Sakeena M.H.F., Bennett A.A., McLachlan A.J. Non-prescription sales of antimicrobial agents at community pharmacies in developing countries: A systematic review. Int. J. Antimicrob. Agents. 2018;52:771-782.
Not in our library10.1016/j.ijantimicag.2018.09.022
124.
Self-medication with Antibiotics in WHO Southeast Asian Region: A Systematic Review · 2018
No notice
125.
Zanichelli V., Tebano G., Gyssens I.C., Vlahović-Palčevski V., Monnier A.A., Benic M.S., Harbarth S., Hulscher M., Pulcini C., Huttner B. Patient-related determinants of antibiotic use: A systematic review. Clin. Microbiol. Infect. 2019;25:48-53.
Not in our library10.1016/j.cmi.2018.04.031
126.
Servia-Dopazo M., Figueiras A. Determinants of antibiotic dispensing without prescription: A systematic review. J. Antimicrob. Chemother. 2018;73:3244-3253.
Not in our library10.1093/jac/dky319
127.
Determinants of Self-Medication With Antibiotics in European and Anglo-Saxon Countries: A Systematic Review of the Literature · 2018
Not checked
128.
Saharman Y.R., Karuniawati A., Severin J.A., Verbrugh H.A. Infections and antimicrobial resistance in intensive care units in lower-middle income countries: A scoping review. Antimicrob. Resist. Infect. Control. 2021;10:22.
Not in our library10.1186/s13756-020-00871-x
129.
Torres N.F., Chibi B., Middleton L.E., Solomon V.P., Mashamba-Thompson T.P. Evidence of factors influencing self-medication with antibiotics in low and middle-income countries: A systematic scoping review. Public Health. 2019;168:92-101.
Not in our library10.1016/j.puhe.2018.11.018
130.
Irek E.O., Amupitan A.A., Obadare T.O., Aboderin A.O. A systematic review of healthcare-associated infections in Africa: An antimicrobial resistance perspective. Afr. J. Lab. Med. 2018;7:9.
Not in our library10.4102/ajlm.v7i2.796
131.
Badia J.M., Casey A.L., Petrosillo N., Hudson P.M., Mitchell S.A., Crosby C. Impact of surgical site infection on healthcare costs and patient outcomes: A systematic review in six European countries. J. Hosp. Infect. 2017;96:1-15.
Not in our library10.1016/j.jhin.2017.03.004
132.
Schreiber P.W., Sax H., Wolfensberger A., Clack L., Kuster S.P. Swissnoso the preventable proportion of healthcare-associated infections 2005–2016: Systematic review and meta-analysis. Infect. Control Hosp. Epidemiol. 2018;39:1277-1295.
Not in our library10.1017/ice.2018.183
133.
Alhomoud F., Aljamea Z., Almahasnah R., Alkhalifah K., Basalelah L., Alhomoud F.K. Self-medication and self-prescription with antibiotics in the Middle East-do they really happen? A systematic review of the prevalence, possible reasons, and outcomes. Int. J. Infect. Dis. 2017;57:3-12.
Not in our library10.1016/j.ijid.2017.01.014
134.
May L.S., Quirós A.M., Ten Oever J., Hoogerwerf J.J., Schoffelen T., Schouten J.A. Antimicrobial stewardship in the emergency department: Characteristics and evidence for effectiveness of interventions. Clin. Microbiol. Infect. 2021;27:204-209.
Not in our library10.1016/j.cmi.2020.10.028
135.
Kalungia A., Godman B. Implications of non-prescription antibiotic sales in China. Lancet Infect. Dis. 2019;19:1272-1273.
Not in our library10.1016/s1473-3099(19)30408-6
136.
Kalungia A.C., Burger J., Godman B., Costa J.D.O., Simuwelu C. Non-prescription sale and dispensing of antibiotics in community pharmacies in Zambia. Expert Rev. Anti-Infect. Ther. 2016;14:1215-1223.
Not in our library10.1080/14787210.2016.1227702
137.
Godman B., Fadare J., Kibuule D., Irawati L., Mubita M., Ogunleye O., Oluka M., Paramadhas B.D.A., Costa J.D.O., De Lemos L.L.P., et al. Initiatives Across Countries to Reduce Antibiotic Utilisation and Resistance Patterns: Impact and Implications. Drug Resistance in Bacteria, Fungi, Malaria, and Cancer. 2017;Volume 34:539-576.
Not in our library
138.
Godman B., McCabe H., DLeong T., Mueller D., Martin A.P., Hoxha I., Mwita J.C., Rwegerera G.M., Massele A., Costa J.D., et al. Fixed dose drug combinations—Are they pharmacoeconomically sound? Findings and impli-cations especially for lower- and middle-income countries. Expert Rev. Pharm. Outcomes Res. 2020;20:1-26.
Not in our library10.1080/14737167.2020.1734456
139.
Godman B., Malmstrom R.E., Diogene E., Jayathissa S., McTaggart S., Cars T., Alvarez-Madrazo S., Baumgärtel C., Brzezinska A., Bucsics A., et al. Dabigatran—A continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. Front. Pharmacol. 2014;5:109.
Not in our library10.3389/fphar.2014.00109
140.
Godman B., Hill A., Simoens S., Selke G., Selke Krulichová I., Zampirolli Dias C., Martin A.P., Oortwijn W., Timoney A., Gustafsson L.L., et al. Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert Rev. Pharm. Outcomes Res. 2021;1-14.
Not in our library10.1080/14737167.2021.1884546
141.
Dias C.Z., Godman B., Gargano L.P., Azevedo P.S., Garcia M.M., Cazarim M.S., Pantuzza L.L., Ribeiro-Junior N.G., Pereira A.L., Borin M.C., et al. Integrative Review of Managed Entry Agreements: Chances and Limitations. PharmacoEconomics. 2020;38:1165-1185.
Not in our library10.1007/s40273-020-00943-1
142.
Godman B., Bucsics A., Vella Bonanno P., Oortwijn W., Rothe C.C., Ferrario A., Bosselli S., Hill A., Martin A., Simoens S., et al. Barriers for Access to New Medicines: Searching for the Balance between Rising Costs and Limited Budgets. Front. Public Health. 2018;6:328.
Not in our library10.3389/fpubh.2018.00328
143.
Policies for biosimilar uptake in Europe: An overview · 2017
No notice
144.
Payers’ views of the changes arising through the possible adoption of Adaptive Pathways · 2016
Not checked
145.
Bochenek T., Abilova V., Alkan A., Asanin B., de Miguel Beriain I., Besovic Z., Bonanno P.V., Bucsics A., Davidescu M., De Weerdt E., et al. Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries. Front. Pharm. 2018;8:942.
Not in our library10.3389/fphar.2017.00942
146.
Godman B., Grobler C., Van-De-Lisle M., Wale J., Barbosa W.B., Massele A., Opondo P., Petrova G., Tachkov K., Sefah I., et al. Pharmacotherapeutic interventions for bipolar disorder type II: Addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income countries. Expert Opin. Pharmacother. 2019;20:2237-2255.
Not in our library10.1080/14656566.2019.1684473
147.
Godman B., Wettermark B., Van Woerkom M., Fraeyman J., Alvarez-Madrazo S., Berg C., Bishop I., Bucsics A., Campbell S., Finlayson A.E., et al. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: Findings and future implications. Front. Pharm. 2014;5:106.
Not in our library10.3389/fphar.2014.00106
148.
World Bank. World Bank Country and Lending Groups—Country Classifictions.
Not in our library
149.
Cameron A., Ewen M., Ross-Degnan D., Ball D., Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: A secondary analysis. Lancet. 2009;373:240-249.
Not in our library10.1016/s0140-6736(08)61762-6
150.
Irrational Use of Medicines—A Summary of Key Concepts · 2016
No notice
151.
Out-of-Pocket Payments, Catastrophic Health Expenditure and Poverty Among Households in Nigeria 2010 · 2018
No notice
152.
Khan J.A.M., Ahmed S., Evans T.G. Catastrophic healthcare expenditure and poverty related to out-of-pocket payments for healthcare in Bangladesh—An estimation of financial risk protection of universal health coverage. Health Policy Plan. 2017;32:1102-1110.
Not in our library10.1093/heapol/czx048
153.
Godman B., Haque M., Islam S., Iqbal S., Urmi U.L., Kamal Z.M., Shuvo S.A., Rahman A., Kamal M., Haque M., et al. Rapid Assessment of Price Instability and Paucity of Medicines and Protection for COVID-19 across Asia: Findings and Public Health Implications for the Future. Front. Public Health. 2020;8:585832.
Not in our library10.3389/fpubh.2020.585832
154.
The household economic burden of non-communicable diseases in 18 countries · 2020
No notice
155.
Rezal R.S., Hassali M.A., Alrasheedy A.A., Saleem F., Aryani Md Yusof F., Kamal M., Din R.M., Godman B. Prescribing patterns for upper respiratory tract infections: A prescription-review of primary care practice in Kedah, Malaysia, and the implications. Expert Rev. Anti-Infect. Ther. 2015;13:1547-1556.
Not in our library10.1586/14787210.2015.1085303
156.
Chowdhury M., Stewart Williams J., Wertheim H., Khan W.A., Matin A., Kinsman J. Rural community perceptions of antibiotic access and understanding of antimicrobial resistance: Qualitative evidence from the Health and Demographic Surveillance System site in Matlab, Bangladesh. Glob. Health Action. 2019;12(Suppl. 1):1824383.
Not in our library10.1080/16549716.2020.1824383
157.
Markovic-Pekovic V., Grubiša N., Burger J., Bojanić L., Godman B. Initiatives to reduce nonprescription sales and dispensing of antibiotics: Findings and implications. J. Res. Pharm. Pract. 2017;6:120.
Not in our library10.4103/jrpp.jrpp_17_12
158.
Nashilongo M.M., Singu B., Kalemeera F., Mubita M., Naikaku E., Baker A., Ferrario A., Godman B., Achieng L., Kibuule D. Assessing Adherence to Antihypertensive Therapy in Primary Health Care in Namibia: Findings and Implications. Cardiovasc. Drugs. 2017;31:565-578.
Not in our library10.1007/s10557-017-6756-8
159.
Saleem Z., Hassali M.A., Hashmi F.K., Godman B., Saleem F. Antimicrobial dispensing practices and determinants of antimicrobial resistance: A qualitative study among community pharmacists in Pakistan. Fam. Med. Community Health. 2019;7:e000138.
Not in our library10.1136/fmch-2019-000138
160.
Chang J., Xu S., Zhu S., Li Z., Yu J., Zhang Y., Zu J., Fang Y., Ross-Degnan D. Assessment of non-prescription antibiotic dispensing at community pharmacies in China with simulated clients: A mixed cross-sectional and longitudinal study. Lancet Infect. Dis. 2019;19:1345-1354.
Not in our library10.1016/s1473-3099(19)30324-x
161.
WHO. Community Pharmacists Are Key Players in COVID-19 Response and Must Stay Up-to-Date on Guidance. 2020.
Not in our library
162.
Hoxha I., Malaj A., Kraja B., Bino S., Oluka M., Markovic-Pekovic V., Godman B. Are pharmacists’ good knowledge and awareness on antibiotics taken for granted? The situation in Albania and future implications across countries. J. Glob. Antimicrob. Resist. 2018;13:240-245.
Not in our library10.1016/j.jgar.2018.01.019
163.
Darj E., Newaz M.S., Zaman M.H. Pharmacists’ perception of their challenges at work, focusing on antimicrobial resistance: A qualitative study from Bangladesh. Glob. Health Action. 2019;12(Suppl. 1):1735126.
Not in our library10.1080/16549716.2020.1735126
164.
Assessment of knowledge and attitude trends towards antimicrobial resistance (AMR) among the community members, pharmacists/pharmacy owners and physicians in district Sialkot, Pakistan · 2019
Not checked
165.
Wettermark B., Godman B., Jacobsson B., Haaijer-Ruskamp F.M. Soft regulations in pharmaceutical policy making: An overview of current approaches and their consequences. Appl. Health Econ. Health Policy. 2009;7:137-147.
Not in our library10.1007/bf03256147
166.
Godman B. Health authority activities to enhance the quality and efficiency of medicine use and their impact. Adv. Hum. Biol. 2021;11:11-16.
Not in our library
167.
Niaz Q., Godman B., Massele A., Campbell S., Kurdi A., Kagoya H.R., Kibuule D. Validity of World Health Organisation prescribing indicators in Namibia’s primary healthcare: Findings and implications. Int. J. Qual. Health Care. 2018;31:338-345.
Not in our library10.1093/intqhc/mzy172
168.
Versporten A., Zarb P., Caniaux I., Gros M.-F., Drapier N., Miller M., Jarlier V., Nathwani D., Goossens H., Koraqi A., et al. Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: Results of an internet-based global point prevalence survey. Lancet Glob. Health. 2018;6:e619-e629.
Not in our library10.1016/s2214-109x(18)30186-4
169.
Nakwatumbah S., Kibuule D., Godman B., Haakuria V., Kalemeera F., Baker A., Mubita M., Mwangana M. Compliance to guidelines for the prescribing of antibiotics in acute infections at Namibia’s national referral hospital: A pilot study and the implications. Expert Rev. Anti-Infect. Ther. 2017;15:713-721.
Not in our library10.1080/14787210.2017.1320220
170.
Niaz Q., Godman B., Campbell S., Kibuule D. Compliance to prescribing guidelines among public health care facilities in Namibia; findings and implications. Int. J. Clin. Pharm. 2020;42:1227-1236.
Not in our library10.1007/s11096-020-01056-7
171.
Afriyie D.K., Sefah I.A., Sneddon J., Malcolm W., McKinney R., Cooper L., Kurdi A., Godman B., Seaton R.A. Antimicrobial point prevalence surveys in two Ghanaian hospitals: Opportunities for antimicrobial stewardship. JAC Antimicrob. Resist. 2020;2:1-9.
Not in our library10.1093/jacamr/dlaa001
172.
Mashalla Y., Setlhare V., Massele A., Sepako E., Tiroyakgosi C., Kgatlwane J., Chuma M., Godman B. Assessment of prescribing practices at the primary healthcare facilities in Botswana with an emphasis on antibiotics: Findings and implications. Int. J. Clin. Pract. 2017;71:e13042.
Not in our library10.1111/ijcp.13042
173.
Sharland M., Gandra S., Huttner B., Moja L., Pulcini C., Zeng M., Mendelson M., Cappello B., Cooke G., Magrini N., et al. Encouraging AWaRe-ness and discouraging inappropriate antibiotic use—The new 2019 Essential Medicines List becomes a global antibiotic stewardship tool. Lancet Infect. Dis. 2019;19:1278-1280.
Not in our library10.1016/s1473-3099(19)30532-8
174.
Saleem Z., Hassali M.A., Godman B., Fatima M., Ahmad Z., Sajid A., Rehman I.U., Nadeem M.U., Javaid Z., Malik M., et al. Sale of WHO AWaRe groups antibiotics without a prescription in Pakistan: A simulated client study. J. Pharm. Policy Pract. 2020;13:26.
Not in our library10.1186/s40545-020-00233-3
175.
Hsia Y., Lee B.R., Versporten A., Yang Y., Bielicki J., Jackson C., Newland J., Goossens H., Magrini N., Sharland M., et al. Use of the WHO Access, Watch, and Reserve classification to define patterns of hospital antibiotic use (AWaRe): An analysis of paediatric survey data from 56 countries. Lancet Glob. Health. 2019;7:e861-e871.
Not in our library10.1016/s2214-109x(19)30071-3
176.
Hoffmann M. The right drug, but from whose perspective? A framework for analysing the structure and activities of drug and therapeutics committees. Eur. J. Clin. Pharm. 2013;69(Suppl. 1):79-87.
Not in our library10.1007/s00228-013-1491-y
177.
Matlala M., Gous A.G.S., Meyer J.C., Godman B. Formulary Management Activities and Practice Implications among Public Sector Hospital Pharmaceutical and Therapeutics Committees in a South African Province. Front. Pharm. 2020;11.
Not in our library10.3389/fphar.2020.01267
178.
Matlala M., Gous A.G., Godman B., Meyer J.C. Structure and activities of pharmacy and therapeutics committees among public hospitals in South Africa; findings and implications. Expert Rev. Clin. Pharm. 2017;10:1273-1280.
Not in our library10.1080/17512433.2017.1364625
179.
Lee M.H., Lee G.A., Lee S.H., Park Y.H. Effectiveness and core components of infection prevention and control programmes in long-term care facilities: A systematic review. J. Hosp. Infect. 2019;102:377-393.
Not in our library10.1016/j.jhin.2019.02.008
180.
Mbui J.M., Oluka M.N., Guantai E.M., Sinei K.A., Achieng L., Baker A., Jande M., Massele A., Godman B. Prescription patterns and adequacy of blood pressure control among adult hypertensive patients in Kenya; findings and implications. Expert Rev. Clin. Pharm. 2017;10:1263-1271.
Not in our library10.1080/17512433.2017.1371590
181.
Matsitse T.B., Helberg E., Meyer J.C., Godman B., Massele A., Schellack N. Compliance with the primary health care treatment guidelines and the essential medicines list in the management of sexually transmitted infections in correctional centres in South Africa: Findings and implications. Expert Rev. Anti-Infect. Ther. 2017;15:963-972.
Not in our library10.1080/14787210.2017.1382354
182.
Brooks J. US Medicare will stop paying for preventable errors. Can. Med. Assoc. J. 2007;177:841-842.
Not in our library10.1503/cmaj.071347
183.
Alrasheedy A.A., Alsalloum M.A., Almuqbil F.A., Almuzaini M.A., Aba Alkhayl B.S., Albishri A.S., Alharbi F.F., Alharbi S.R., Alodhayb A.K., Alfadl A.A., et al. The impact of law enforcement on dispensing antibiotics without prescription: A multi-methods study from Saudi Arabia. Expert Rev. Anti-Infect. Ther. 2020;18:87-97.
Not in our library10.1080/14787210.2020.1705156
184.
Godman B., Basu D., Pillay Y., Almeida P.H., Mwita J.C., Rwegerera G.M., Paramadhas B.D.A., Tiroyakgosi C., Patrick O., Niba L.L., et al. Ongoing and planned activities to improve the management of patients with Type 1 diabetes across Africa; implications for the future. Hosp. Pract. 2020;48:51-67.
Not in our library10.1080/21548331.2020.1745509
185.
Godman B., Basu D., Pillay Y., Mwita J.C., Rwegerera G.M., Anand Paramadhas B.D., Tiroyakgosi C., Okwen P.M., Niba L.L., Nonvignon J., et al. Review of Ongoing Activities and Challenges to Improve the Care of Patients with Type 2 Diabetes across Africa and the Implications for the Future. Front. Pharm. 2020;11:108.
Not in our library10.3389/fphar.2020.00108
186.
WHO. Health Care-Associated Infections. 2014.
Not in our library
187.
Mugomeri E. The efficacy of infection prevention and control committees in Lesotho: A qualitative study. Am. J. Infect. Control. 2018;46:e13-e17.
Not in our library10.1016/j.ajic.2017.11.028
188.
Gilbert G.L., Kerridge I. The politics and ethics of hospital infection prevention and control: A qualitative case study of senior clinicians’ perceptions of professional and cultural factors that influence doctors’ attitudes and practices in a large Australian hospital. BMC Health Serv. Res. 2019;19:212.
Not in our library10.1186/s12913-019-4044-y
189.
Mpinda-Joseph P., Anand Paramadhas B.D., Reyes G., Maruatona M.B., Chise M., Monokwane-Thupiso B.B., Souda S., Tiroyakgosi C., Godman B. Healthcare-associated infections including neonatal bloodstream infections in a leading tertiary hospital in Botswana. Hosp. Pract. 2019;47:203-210.
Not in our library10.1080/21548331.2019.1650608
190.
WHO. Minimum Requirements for Infection Prevention and Control Programmes. 2019.
Not in our library
191.
Li M., Wang X., Wang J., Tan R., Sun J., Li L., Huang J., Wu J., Gu Q., Zhao Y., et al. Infection-prevention and control interventions to reduce colonisation and infection of intensive care unit-acquired carbapenem-resistant Klebsiella pneumoniae: A 4-year quasi-experimental before-and-after study. Antimicrob. Resist. Infect. Control. 2019;8:8.
Not in our library10.1186/s13756-018-0453-7
192.
Infection Control Africa Network (ICAN). Training Course: Infection Prevention and Control for Healthcare Workers 12–16 April 2021.
Not in our library
193.
Kurdi A., Hasan A.J., Baker K.I., Seaton R.A., Ramzi Z.S., Sneddon J., Godman B. A multicentre point prevalence survey of hospital antibiotic prescribing and quality indices in the Kurdistan Regional Government of Northern Iraq: The need for urgent action. Expert Rev. Anti-Infect. Ther. 2021;19:805-814.
Not in our library10.1080/14787210.2021.1834852
194.
Momanyi L., Opanga S., Nyamu D., Oluka M., Kurdi A., Godman B. Antibiotic prescribing patterns at a leading referral hospital in Kenya: A point prevalence survey. J. Res. Pharm. Pract. 2019;8:149-154.
Not in our library10.4103/jrpp.jrpp_18_68
195.
Allegranzi B., Bagheri Nejad S., Chraiti M., Combescure C., Attar H., Pittet D. Report on the Burden of Endemic Health Care-Associated Infection Worldwide. 2011.
Not in our library
196.
Prevention E.C.f.D., Control Suetens C., Hopkins S., Kolman J., Högberg L.D. Point Prevalence Survey of Healthcare-Associated Infections and Antimicrobial Use in European Acute Care Hospitals: 2011–2012. 2013.
Not in our library
197.
Nejad S.B., Allegranzi B., Syed S.B., Ellis B., Pittet D. Health-care-associated infection in Africa: A systematic review. Bull. WHO. 2011;89:757-765.
Not in our library10.2471/blt.11.088179
198.
Rothe C., Schlaich C., Thompson S. Healthcare-associated infections in sub-Saharan Africa. J. Hosp. Infect. 2013;85:257-267.
Not in our library10.1016/j.jhin.2013.09.008
199.
Umscheid C.A., Mitchell M.D., Doshi J.A., Agarwal R., Williams K., Brennan P.J. Estimating the Proportion of Healthcare-Associated Infections That Are Reasonably Preventable and the Related Mortality and Costs. Infect. Control Hosp. Epidemiol. 2011;32:101-114.
Not in our library10.1086/657912
200.
Manoukian S., Stewart S., Dancer S., Graves N., Mason H., McFarland A., Robertson C., Reilly J. Estimating excess length of stay due to healthcare-associated infections: A systematic review and meta-analysis of statistical methodology. J. Hosp. Infect. 2018;100:222-235.
Not in our library10.1016/j.jhin.2018.06.003
201.
Ataiyero Y., Dyson J., Graham M. Barriers to hand hygiene practices among health care workers in sub-Saharan African countries: A narrative review. Am. J. Infect. Control. 2019;47:565-573.
Not in our library10.1016/j.ajic.2018.09.014
202.
Afriyie D.K., Amponsah S.K., Dogbey J., Agyekum K., Kesse S., Truter I., Meyer J.C., Godman B. A pilot study evaluating the prescribing of ceftriaxone in hospitals in Ghana: Findings and implications. Hosp. Pract. 2017;45:143-149.
Not in our library10.1080/21548331.2017.1348139
203.
Dlamini N.N., Meyer J.C., Kruger D., Kurdi A., Godman B., Schellack N. Feasibility of using point prevalence surveys to assess antimicrobial utilisation in public hospitals in South Africa: A pilot study and implications. Hosp. Pract. 2019;47:88-95.
Not in our library10.1080/21548331.2019.1592880
204.
Kruger D., Dlamini N.N., Meyer J.C., Godman B., Kurdi A., Lennon M., Bennie M., Schellack N. Development of a web-based application to improve data collection of antimicrobial utilization in the public health care system in South Africa. Hosp. Pract. 2021;2021:1-10.
Not in our library10.1080/21548331.2021.1889213
205.
Skosana P.P., Schellack N., Godman B., Kurdi A., Bennie M., Kruger D., Meyer J. A point prevalence survey of antimicrobial utilisation patterns and quality indices amongst hospitals in South Africa; findings and implications. Expert Rev. Anti-Infect. Ther. 2021;2021:1-13.
Not in our library10.1080/14787210.2021.1898946
206.
BSAC. Practical Guide to Antimicrobial Stewardship in Hospitals. 2013.
Not in our library
207.
BSAC. Antimicrobial Stewardship from Principles to Practice. 2018.
Not in our library
208.
Commonwealth Partnerships for Antimicrobial Stewardship. Working Together to Tackle Antimicrobial Resistance in the Commonwealth. 2020.
Not in our library
209.
World Health Organization. Antimicrobial Stewardship Programmes in Health-Care Facilities in Low- and Mid-Dle-Income Countries. A Who Practical Toolkit. 2019.
Not in our library
210.
Pulcini C., Binda F., Lamkang A.S., Trett A., Charani E., Goff D., Harbarth S., Hinrichsen S., Levy-Hara G., Mendelson M., et al. Developing core elements and checklist items for global hospital antimicrobial stewardship programmes: A consensus approach. Clin. Microbiol. Infect. 2019;25:20-25.
Not in our library10.1016/j.cmi.2018.03.033
211.
CDC. The Core Elements of Human Antibiotic Stewardship Programs in Resource-Limited Settings: National and Hospital Levels.
Not in our library
212.
Vu T.L., Vu Q.D., Hoang B.L., Nguyen T.C., Ta T.D., Nadjm B., van Doorn H.R. Factors influencing choices of empirical antibiotic treatment for bacterial infections in a scenario-based survey in Vietnam. JAC-Antimicrob. Resist. 2020;2:dlaa087.
Not in our library10.1093/jacamr/dlaa087
213.
Kakkar A.K., Shafiq N., Singh G., Ray P., Gautam V., Agarwal R., Muralidharan J., Arora P. Antimicrobial Stewardship Programs in Resource Constrained Environments: Understanding and Addressing the Need of the Systems. Front. Public Health. 2020;8:140.
Not in our library10.3389/fpubh.2020.00140
214.
Fadare J.O., Ogunleye O., Iliyasu G., Adeoti A., Schellack N., Engler D., Massele A., Godman B. Status of antimicrobial stewardship programmes in Nigerian tertiary healthcare facilities: Findings and implications. J. Glob. Antimicrob. Resist. 2019;17:132-136.
Not in our library10.1016/j.jgar.2018.11.025
215.
Kalungia A.C., Mwambula H., Munkombwe D., Marshall S., Schellack N., May C., Jones A.S.C., Godman B. Antimicrobial stewardship knowledge and perception among physicians and pharmacists at leading tertiary teaching hospitals in Zambia: Implications for future policy and practice. J. Chemother. 2019;31:378-387.
Not in our library10.1080/1120009x.2019.1622293
216.
Opportunities and barriers to implementing antibiotic stewardship in low and middle-income countries: Lessons from a mixed-methods study in a tertiary care hospital in Ethiopia. · 2018
Not checked
217.
Schellack N., Bronkhorst E., Coetzee R., Godman B., Gous A.G.S., Kolman SCoetzee R., Bronkhorst E. SASOCP position statement on the pharmacist’s role in antibiotic stewardship South African. J. Infect. Dis. 2018;33:28-35.
Not in our library
218.
Okoth C., Opanga S., Okalebo F., Oluka M., Baker Kurdi A., Godman B. Point prevalence survey of antibiotic use and resistance at a referral hospital in Kenya: Findings and implications. Hosp. Pract. 2018;46:128-136.
Not in our library10.1080/21548331.2018.1464872
219.
Lew K.Y., Ng T.M., Tan M., Tan S.H., Lew E.L., Ling L.M., Ang B., Lye D., Teng C.B. Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting. J. Antimicrob. Chemother. 2014;70:1219-1225.
Not in our library10.1093/jac/dku479
220.
Stanic Benic M., Milanic R., Monnier A.A., Gyssens I.C., Adriaenssens N., Versporten A., Zanichelli V., Le Maréchal M., Huttner B., Tebano G., et al. Metrics for quantifying antibiotic use in the hospital setting: Results from a systematic review and international multidisciplinary consensus procedure. J. Antimicrob. Chemother. 2018;73(Suppl. 6):vi50-vi58.
Not in our library10.1093/jac/dky118
221.
Mauger B., Marbella A., Pines E., Chopra R., Black E.R., Aronson N. Implementing quality improvement strategies to reduce healthcare-associated infections: A systematic review. Am. J. Infect. Control. 2014;42:S274-S283.
Not in our library10.1016/j.ajic.2014.05.031
222.
Comparative efficacy of interventions to promote hand hygiene in hospital: systematic review and network meta-analysis · 2015
No notice
223.
Loftus M.J., Guitart C., Tartari E., Stewardson A.J., Amer F., Bellissimo-Rodrigues F., Lee Y.F., Mehtar S., Sithole B.L., Pittet D. Hand hygiene in low- and middle-income countries. Int. J. Infect. Dis. 2019;86:25-30.
Not in our library10.1016/j.ijid.2019.06.002
224.
WHO. Hand Hygiene Self-Assessment Framework.
Not in our library
225.
Malhotra N.R., Piazza M., Demoor R., McClintock S.D., Hamilton K., Sharma N., Osiemo B., Berger I., Hossain E., Borovskiy Y., et al. Impact of Reduced Preincision Antibiotic Infusion Time on Surgical Site Infection Rates: A Retrospective Cohort Study. Ann. Surg. 2020;271:774-780.
Not in our library10.1097/sla.0000000000003030
226.
Najjar P.A., Smink D.S. Prophylactic Antibiotics and Prevention of Surgical Site Infections. Surg. Clin. N. Am. 2015;95:269-283.
Not in our library10.1016/j.suc.2014.11.006
227.
de Jonge S.W., Gans S.L., Atema J.J., Solomkin J.S., Dellinger P.E., Boermeester M.A. Timing of preoperative antibiotic prophylaxis in 54,552 patients and the risk of surgical site infection: A systematic review and meta-analysis. Medicine. 2017;96:e6903.
Not in our library10.1097/md.0000000000006903
228.
Branch-Elliman W., O’Brien W., Strymish J., Itani K., Wyatt C., Gupta K. Association of Duration and Type of Surgical Prophylaxis with Antimicrobial-Associated Adverse Events. JAMA Surg. 2019;154:590-598.
Not in our library10.1001/jamasurg.2019.0569
229.
Saito H., Inoue K., Ditai J., Weeks A.D. Pattern of Peri-Operative Antibiotic Use among Surgical Patients in a Regional Referral and Teaching Hospital in Uganda. Surg. Infect. 2020;21:540-546.
Not in our library10.1089/sur.2019.176
230.
Harbarth S., Samore M.H., Lichtenberg D., Carmeli Y. Prolonged Antibiotic Prophylaxis after Cardiovascular Surgery and Its Effect on Surgical Site Infections and Antimicrobial Resistance. Circulation. 2000;101:2916-2921.
Not in our library10.1161/01.cir.101.25.2916
231.
Hawn M.T., Knowlton L.M. Balancing the Risks and Benefits of Surgical Prophylaxis: Timing and Duration Do Matter. JAMA Surg. 2019;154:598-599.
Not in our library10.1001/jamasurg.2019.0570
232.
Bull A.L., Worth L.J., Spelman T., Richards M.J. Antibiotic Prescribing Practices for Prevention of Surgical Site Infections in Australia: Increased Uptake of National Guidelines after Surveillance and Reporting and Impact on Infection Rates. Surg. Infect. 2017;18:834-840.
Not in our library10.1089/sur.2017.119
233.
Langerman A., Thisted R., Hohmann S., Howell M. Antibiotic and Duration of Perioperative Prophylaxis Predicts Surgical Site Infection in Head and Neck Surgery. Otolaryngol. Neck Surg. 2016;154:1054-1063.
Not in our library10.1177/0194599816634303
234.
Vicentini C., Politano G., Corcione S., Furmenti M.F., Quattrocolo F., De Rosa F.G., Zotti C.M. Surgical antimicrobial prophylaxis prescribing practices and impact on infection risk: Results from a multicenter surveillance study in Italy (2012–2017). Am. J. Infect. Control. 2019;47:1426-1430.
Not in our library10.1016/j.ajic.2019.07.013
235.
Nthumba P.M. Effective Hand Preparation for Surgical Procedures in Low- and Middle-Income Countries. Surg. Infect. 2020;21:495-500.
Not in our library10.1089/sur.2020.025
236.
Davey P., Peden C., Brown E., Charani E., Michie S., Ramsay C.R., Marwick C.A. Interventions to improve antibiotic prescribing practices for hospital inpatients (updated protocol). Cochrane Database Syst. Rev. 2014;2:Cd003543.
Not in our library10.1002/14651858.cd011236
237.
McLeod M., Ahmad R., Shebl N.A., Micallef C., Sim F., Holmes A. A whole-health–economy approach to antimicrobial stewardship: Analysis of current models and future direction. PLoS Med. 2019;16:e1002774.
Not in our library10.1371/journal.pmed.1002774
238.
Curtis C.E., Al Bahar F., Marriott J.F. The effectiveness of computerised decision support on antibiotic use in hospitals: A systematic review. PLoS ONE. 2017;12:e0183062.
Not in our library10.1371/journal.pone.0183062
239.
Tahoon M.A., Khalil M.M., Hammad E., Morad W.S., Awad S.M., Ezzat S. The effect of educational intervention on healthcare providers’ knowledge, attitude, & practice towards antimicrobial stewardship program at, National Liver Institute, Egypt. Egypt. Liver J. 2020;10:5.
Not in our library
240.
Majumder M.A.A., Singh K., Hilaire M.G., Rahman S., Sa B., Haque M. Tackling Antimicrobial Resistance by promoting Anti-microbial stewardship in Medical and Allied Health Professional Curricula. Expert Rev. Anti-Infect. Ther. 2020;18:1245-1258.
Not in our library10.1080/14787210.2020.1796638
241.
Bozkurt F., Kaya S., Tekin R., Gulsun S., Deveci O., Dayan S., Hosoglu S. Analysis of antimicrobial consumption and cost in a teaching hospital. J. Infect. Public Health. 2014;7:161-169.
Not in our library10.1016/j.jiph.2013.09.007
242.
Hou D., Wang Q., Jiang C., Tian C., Li H., Ji B. Evaluation of the Short-Term Effects of Antimicrobial Stewardship in the Intensive Care Unit at a Tertiary Hospital in China. PLoS ONE. 2014;9:e101447.
Not in our library10.1371/journal.pone.0101447
243.
Amdany H.K., McMillan M. Metronidazole intravenous formulation use in in-patients in Kapkatet District Hospital, Kenya: A best practice implementation project. JBI Database Syst. Rev. Implement. Rep. 2014;12:419-432.
Not in our library10.11124/jbisrir-2014-1381
244.
DRUGS system enhancing adherence of Chinese surgeons to antibiotic use guidelines during perioperative period. · 2014
Not checked
245.
Okumura L.M., Da Silva M.M.G., Veroneze I. Effects of a bundled Antimicrobial Stewardship Program on mortality: A cohort study. Braz. J. Infect. Dis. 2015;19:246-252.
Not in our library10.1016/j.bjid.2015.02.005
246.
A cost-effectiveness analysis of two different antimicrobial stewardship programs · 2016
Not checked
247.
Saied T., Hafez S.F., Kandeel A., El-Kholy A., Ismail G., Aboushady M., Attia E., Hassaan A., Abdel-Atty O., Elfekky E., et al. Antimicrobial stewardship to optimize the use of antimicrobials for surgical prophylaxis in Egypt: A multicenter pilot intervention study. Am. J. Infect. Control. 2015;43:e67-e71.
Not in our library10.1016/j.ajic.2015.07.004
248.
Ntumba P., Mwangi C., Barasa J., Aiken A.M., Kubilay Z., Allegranzi B. Multimodal approach for surgical site infection prevention—Results from a pilot site in Kenya. Antimicrob. Resist. Infect. Control. 2015;4:87.
Not in our library10.1186/2047-2994-4-s1-p87
249.
Apisarnthanarak A., Lapcharoen P., Vanichkul P., Srisaeng-Ngoen T., Mundy L.M. Design and analysis of a pharmacist-enhanced antimicrobial stewardship program in Thailand. Am. J. Infect. Control. 2015;43:956-959.
Not in our library10.1016/j.ajic.2015.05.011
250.
Boyles T.H., Naicker V., Rawoot N., Raubenheimer P.J., Eick B., Mendelson M. Sustained reduction in antibiotic consumption in a South African public sector hospital; Four year outcomes from the Groote Schuur Hospital antibiotic stewardship program. S. Afr. Med. J. 2017;107:115-118.
Not in our library10.7196/samj.2017.v107i2.12067
251.
Brink A.J., Messina A.P., Feldman C., Richards G.A., van den Bergh D. From guidelines to practice: A pharmacist-driven prospective audit and feedback improvement model for perioperative antibiotic prophylaxis in 34 South African hospitals. J. Antimicrob. Chemother. 2016;72:1227-1234.
Not in our library10.1093/jac/dkw523
252.
Allegranzi B., Aiken A.M., Zeynep Kubilay N., Nthumba P., Barasa J., Okumu G., Mugarura R., Elobu A., Jombwe J., Maimbo M., et al. A multimodal infection control and patient safety intervention to reduce surgical site infections in Africa: A multicentre, before–after, cohort study. Lancet Infect. Dis. 2018;18:507-515.
Not in our library10.1016/s1473-3099(18)30107-5
253.
Khdour M.R., Hallak H.O., Aldeyab M.A., Nasif M.A., Khalili A.M., Dallashi A.A., Khofash M.B., Scott M.G. Impact of antimicrobial stewardship programme on hospitalized patients at the intensive care unit: A prospective audit and feedback study. Br. J. Clin. Pharmacol. 2018;84:708-715.
Not in our library10.1111/bcp.13486
254.
Abubakar U., Syed Sulaiman S.A., Adesiyun A.G. Impact of pharmacist-led antibiotic stewardship interventions on compliance with surgical antibiotic prophylaxis in obstetric and gynecologic surgeries in Nigeria. PLoS ONE. 2019;14:e0213395.
Not in our library10.1371/journal.pone.0213395
255.
Karaali C., Emiroglu M., Atalay S., Sert I., Dursun A., Kose S., Akbulut G., Aydın C. A new antibiotic stewardship program approach is effective on inappropriate surgical prophylaxis and discharge prescription. J. Infect. Dev. Ctries. 2019;13:961-967.
Not in our library10.3855/jidc.11734
256.
Mahmoudi L., Ghouchani M., Mahi-Birjand M., Bananzadeh A., Akbari A. Optimizing compliance with surgical antimicrobial prophylaxis guidelines in patients undergoing gastrointestinal surgery at a referral teaching hospital in southern Iran: Clinical and economic impact. Infect. Drug Resist. 2019;12:2437-2444.
Not in our library10.2147/idr.s212728
257.
Xiao Y., Shen P., Zheng B., Zhou K., Luo Q., Li L. Change in Antibiotic Use in Secondary and Tertiary Hospitals Nationwide after a National Antimicrobial Stewardship Campaign Was Launched in China, 2011–2016: An Observational Study. J. Infect. Dis. 2020;221:S148-S155.
Not in our library10.1093/infdis/jiz556
258.
Mardani M., Abolghasemi S., Shabani S. Impact of an antimicrobial stewardship program in the antimicrobial-resistant and prevalence of clostridioides difficile infection and amount of antimicrobial consumed in cancer patients. BMC Res. Notes. 2020;13:246.
Not in our library10.1186/s13104-020-05085-3
259.
van den Bergh D., Messina A.P., Goff D.A., van Jaarsveld A., Coetzee R., de Wet Y., Bronkhorst E., Brink A., Mendelson M., Richards G.A. A pharmacist-led prospective antibiotic stewardship intervention improves compliance to community-acquired pneumonia guidelines in 39 public and private hospitals across South Africa. Int. J. Antimicrob. Agents. 2020;56:106189.
Not in our library10.1016/j.ijantimicag.2020.106189
260.
Dinh A., Duran C., Davido B., Bouchand F., Deconinck L., Matt M., Sénard O., Guyot C., Levasseur A.-S., Attal J., et al. Impact of an antimicrobial stewardship programme to optimize antimicrobial use for outpatients at an emergency department. J. Hosp. Infect. 2017;97:288-293.
Not in our library10.1016/j.jhin.2017.07.005
261.
Bishop B.M. Antimicrobial Stewardship in the Emergency Department: Challenges, Opportunities, and a Call to Action for Pharmacists. J. Pharm. Pract. 2015;29:556-563.
Not in our library10.1177/0897190015585762
262.
Acosta A., Vanegas E.P., Rovira J., Godman B., Bochenek T. Medicine Shortages: Gaps between Countries and Global Perspectives. Front. Pharm. 2019;10.
Not in our library10.3389/fphar.2019.00763
263.
Modisakeng C., Matlala M., Godman B., Meyer J.C. Medicine shortages and challenges with the procurement process among public sector hospitals in South Africa; findings and implications. BMC Health Serv. Res. 2020;20:234.
Not in our library10.1186/s12913-020-05080-1
264.
Chigome A.K., Matlala M., Godman B., Meyer J.C. Availability and Use of Therapeutic Interchange Policies in Managing Antimicrobial Shortages among South African Public Sector Hospitals; Findings and Implications. Antibiotics. 2019;9:4.
Not in our library10.3390/antibiotics9010004
265.
Gundlapalli A.V., Beekmann S.E., Graham D.R., Polgreen P.M. Perspectives and concerns regarding antimicrobial agent shortages among infectious disease specialists. Diagn. Microbiol. Infect. Dis. 2013;75:256-259.
Not in our library10.1016/j.diagmicrobio.2012.11.020
266.
Pulcini C., Beovic B., Béraud G., Carlet J., Cars O., Howard P., Levy-Hara G., Li G., Nathwani D., Roblot F., et al. Ensuring universal access to old antibiotics: A critical but neglected priority. Clin. Microbiol. Infect. 2017;23:590-592.
Not in our library10.1016/j.cmi.2017.04.026
267.
Schellack N., Coetzee M., Schellack G., Gijzelaar M., Hassim Z., Milne M., Bronkhorst E., Padayachee N., Singh N., Kolman S., et al. COVID-19: Guidelines for pharmacists in South Africa. S. Afr. J. Infect. Dis. 2020;35:10.
Not in our library10.4102/sajid.v35i1.206
268.
Uzochukwu B., Onwujekwe O., Eriksson B. Inequity in the Bamako Initiative programme—Implications for the treatment of malaria in south-east Nigeria. Int. J. Health Plan. Manag. 2004;19:S107-S116.
Not in our library10.1002/hpm.779
269.
Omololu F.O., Okunola R.A., Salami K.K. Equity and access to health care services: The experience of the Bamako initiative programme in Nigeria. J. Med. Med. Sci. 2012;3:434-442.
Not in our library
270.
Ogbonna B.O., Nwako N.N. Essential Drugs Revolving Fund Scheme in Nigeria; from the Edge of a Precipice towards Sustainability. J. Adv. Med. Pharm. Sci. 2016;8:1-8.
Not in our library10.9734/jamps/2016/25950
271.
Shaikhan F., Rawaf S., Majeed A., Hassounah S. Knowledge, attitude, perception and practice regarding antimicrobial use in upper respiratory tract infections in Qatar: A systematic review. JRSM Open. 2018;9:2054270418774971.
Not in our library10.1177/2054270418774971
272.
Erku D.A., Mekuria A.B., Belachew S.A. Inappropriate use of antibiotics among communities of Gondar town, Ethiopia: A threat to the development of antimicrobial resistance. Antimicrob. Resist. Infect. Control. 2017;6:112.
Not in our library10.1186/s13756-017-0272-2
273.
Wei X., Zhang Z., Hicks J.P., Walley J.D., King R., Newell J.N., Yin J., Zeng J., Guo Y., Lin M., et al. Long-term outcomes of an educational intervention to reduce antibiotic prescribing for childhood upper respiratory tract infections in rural China: Follow-up of a cluster-randomised controlled trial. PLoS Med. 2019;16:e1002733.
Not in our library10.1371/journal.pmed.1002733
274.
Holloway K.A., Ivanovska V., Wagner A.K., Vialle-Valentin C., Ross-Degnan D. Prescribing for acute childhood infections in developing and transitional countries, 1990–2009. Paediatr. Int. Child Health. 2015;35:5-13.
Not in our library10.1179/2046905514y.0000000115
275.
Kibuule D., Kagoya H.R., Godman B. Antibiotic use in acute respiratory infections in under-fives in Uganda: Findings and implications. Expert Rev. Anti-Infect. Ther. 2016;14:863-872.
Not in our library10.1080/14787210.2016.1206468
276.
Farley E., Stewart A., Davies M.-A., Govind M., Van den Bergh D., Boyles T.H. Antibiotic use and resistance: Knowledge, attitudes and perceptions among primary care prescribers in South Africa. S. Afr. Med. J. 2018;108:763-771.
Not in our library10.7196/samj.2018.v108i9.12933
277.
Teng C.L., Achike F.I., Phua K.L., Nurjahan M.I., Mastura I., Asiah H.N., Mariam A.M., Narayanan S., Norsiah A., Sabariah I., et al. Modifying antibiotic prescribing: The effectiveness of academic detailing plus information leaflet in a Malaysian primary care setting. Med. J. Malays. 2006;61:323-331.
Not in our library
278.
Shrestha N., Samir K.C., Baltussen R., Kafle K.K., Bishai D., Niessen L. Practical Approach to Lung Health in Nepal: Better prescribing and reduction of cost. Trop. Med. Int. Health. 2006;11:765-772.
Not in our library10.1111/j.1365-3156.2006.01599.x
279.
Awad A.I., Eltayeb I.B., Baraka O.Z. Changing antibiotics prescribing practices in health centers of Khartoum State, Sudan. Eur. J. Clin. Pharm. 2006;62:135-142.
Not in our library10.1007/s00228-005-0089-4
280.
Kafle K.K., Bhuju G.B., Karkee S.B., Prasad R.R., Shrestha N., Shrestha A.D., Das P.L., Chataut P.D., Daud M. An intervention improving prescribing practices and monitoring drugs availability in a district. Nepal Med. Coll. J. 2009;11:217-221.
Not in our library
281.
Yip W., Powell-Jackson T., Chen W., Hu M., Fe E., Hu M., Jian W., Lu M., Han W., Hsiao W.C. Capitation combined with pay-for-performance improves antibiotic prescribing practices in rural China. Health Aff. 2014;33:502-510.
Not in our library10.1377/hlthaff.2013.0702
282.
Boonyasiri A., Thamlikitkul V. Effectiveness of multifaceted interventions on rational use of antibiotics for patients with upper respiratory tract infections and acute diarrhea. J. Med. Assoc. Thail. Chotmaihet Thangphaet. 2014;97(Suppl. 3):S13-S19.
Not in our library
283.
Tay K.H., Ariffin F., Sim B.L., Chin S.Y., Sobry A.C. Multi-Faceted Intervention to Improve the Antibiotic Prescriptions among Doctors for Acute URI and Acute Diarrhoea Cases: The Green Zone Antibiotic Project. Malays. J. Med. Sci. 2019;26:101-109.
Not in our library10.21315/mjms2019.26.4.12
284.
Prescribing indicators at primary health care centers within the WHO African region: a systematic analysis (1995–2015) · 2016
No notice
285.
Rwegerera G.M., Shailemo D.H.P., Pina Rivera Y., Mokgosi K.O., Bale P., Oyewo T.A., Luis B.D., Habte D., Godman B. Metabolic Control and Determinants among HIV-Infected Type 2 Diabetes Mellitus Patients Attending a Tertiary Clinic in Botswana. Diabetes Metab. Syndr. Obes. 2021;14:85-97.
Not in our library10.2147/dmso.s285720
286.
Mwita J.C., Godman B., Esterhuizen T.M. Statin prescription among patients with type 2 diabetes in Botswana: Findings and implications. BMC Endocr. Disord. 2020;20:36.
Not in our library10.1186/s12902-020-0516-7
287.
Achwoka D., Waruru A., Chen T.-H., Masamaro K., Ngugi E., Kimani M., Mukui I., Oyugi J.O., Mutave R., Achia T., et al. Noncommunicable disease burden among HIV patients in care: A national retrospective longitudinal analysis of HIV-treatment outcomes in Kenya, 2003–2013. BMC Public Health. 2019;19:372.
Not in our library10.1186/s12889-019-6716-2
288.
Appiah L.T., Sarfo F.S., Huffman M.D., Nguah S.B., Stiles J.K. Cardiovascular risk factors among Ghanaian patients with HIV: A cross-sectional study. Clin. Cardiol. 2019;42:1195-1201.
Not in our library10.1002/clc.23273
289.
Chang A.Y., Gómez-Olivé F.X., Manne-Goehler J., Wade A.N., Tollman S., Gaziano T.A., Salomon J.A. Multimorbidity and care for hypertension, diabetes and HIV among older adults in rural South Africa. Bull. World Health Organ. 2018;97:10-23.
Not in our library10.2471/blt.18.217000
290.
Fernandez Urrusuno R., Flores Dorado M., Vilches Arenas A., Serrano Martino C., Corral Baena S., Montero Balosa M.C. Improving the appropriateness of antimicrobial use in primary care after implementation of a local antimicrobial guide in both levels of care. Eur. J. Clin. Pharmacol. 2014;70:1011-1020.
Not in our library10.1007/s00228-014-1704-z
291.
Kibuule D., Mubita M., Naikaku E., Kalemeera F., Godman B.B., Sagwa E. An analysis of policies for cotrimoxazole, amoxicillin and azithromycin use in Namibia’s public sector: Findings and therapeutic implications. Int. J. Clin. Pract. 2017;71:e12918.
Not in our library10.1111/ijcp.12918
292.
Mashalla Y.J., Sepako E., Setlhare V., Chuma M., Bulang M., Massele A.Y. Availability of guidelines and policy documents for enhancing performance of practitioners at the Primary Health Care (PHC) facilities in Gaborone, Tlokweng and Mogoditshane, Republic of Botswana. J. Public Health Epidemiol. 2016;8:127-135.
Not in our library
293.
Ongoing Initiatives to Improve the Quality and Efficiency of Medicine Use within the Public Healthcare System in South Africa; A Preliminary Study · 2017
No notice
294.
Rossato L., Negrão F.J., Simionatto S. Could the COVID-19 pandemic aggravate antimicrobial resistance? Am. J. Infect. Control. 2020;48:1129-1130.
Not in our library10.1016/j.ajic.2020.06.192
295.
Ray K.N., Shi Z., Gidengil C.A., Poon S.J., Uscher-Pines L., Mehrotra A. Antibiotic Prescribing During Pediatric Direct-to-Consumer Telemedicine Visits. Pediatrics. 2019;143:e20182491.
Not in our library10.1542/peds.2018-2491
296.
Hayat K., Li P., Rosenthal M., Xu S., Chang J., Gillani A.H., Khan F.U., Sarwar M.R., Ji S., Shi L., et al. Perspective of community pharmacists about community-based antimicrobial stewardship programs. A multicenter cross-sectional study from China. Expert Rev. Anti-Infect. Ther. 2019;17:1043-1050.
Not in our library10.1080/14787210.2019.1692655
297.
Poyongo B.P., Sangeda R.Z. Pharmacists’ Knowledge, Attitude and Practice Regarding the Dispensing of Antibiotics without Prescription in Tanzania: An Explorative Cross-Sectional Study. Pharmacy. 2020;8:238.
Not in our library10.3390/pharmacy8040238
298.
Zawahir S., Lekamwasam S., Aslani P. A cross-sectional national survey of community pharmacy staff: Knowledge and anti-biotic provision. PLoS ONE. 2019;14:e0215484.
Not in our library10.1371/journal.pone.0215484
299.
Haque M., Kumar S., Charan J., Bhatt R., Islam S., Dutta S., Abhayanand J.P., Sharma Y., Sefah I.A., Kurdi A., et al. Utilisation, availability and price changes of medicines and protection equipment for COVID-19 in India: Findings and implications Short title: COVID-19 and price changes of treatments in India. Front. Pharmacol. 2021;11:1822.
Not in our library10.3389/fphar.2020.582154
300.
Selvaraj S., Farooqui H.H., Karan A. Quantifying the financial burden of households’ out-of-pocket payments on medicines in India: A repeated cross-sectional analysis of National Sample Survey data, 1994–2014. BMJ Open. 2018;8:e018020.
Not in our library10.1136/bmjopen-2017-018020
301.
Essack S., Bell J., Shephard A. Community pharmacists-Leaders for antibiotic stewardship in respiratory tract infection. J. Clin. Pharm. Ther. 2018;43:302-307.
Not in our library10.1111/jcpt.12650
302.
Wirtz V., Herrera-Patino J.J., Santa-Ana-Tellez Y., Dreser A., Elseviers M., Vander Stichele R. Analysing policy interventions to prohibit over-the-counter antibiotic sales in four Latin American countries. Trop. Med. Int. Health. 2013;18:665-673.
Not in our library10.1111/tmi.12096
303.
Vacca C.P., Niño C.Y., Reveiz L. Restriction of antibiotic sales in pharmacies in Bogotá, Colombia: A descriptive study. Rev. Panam. De Salud Pública. 2011;30:586-591.
Not in our library
304.
Godman B., Sakshaug S., Berg C., Wettermark B., Haycox A. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Rev. Pharm. Outcomes Res. 2011;11:121-129.
Not in our library10.1586/erp.10.87
305.
Voncina L., Strizrep T., Godman B., Bennie M., Bishop I., Campbell S., Vlahović-Palčevski V., Gustafsson L.L. Influence of demand-side measures to enhance ren-in-angiotensin prescribing efficiency in Europe: Implications for the future. Expert Rev. Pharm. Outcomes Res. 2011;11:469-479.
Not in our library10.1586/erp.11.42
306.
Godman B., Bishop I., Finlayson A.E., Campbell S., Kwon H.-Y., Bennie M. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Rev. Pharm. Outcomes Res. 2013;13:469-482.
Not in our library10.1586/14737167.2013.820956
307.
Santa-Ana-Tellez Y., Mantel-Teeuwisse A.K., Dreser A., Leufkens H.G., Wirtz V.J. Impact of over-the-counter restrictions on antibiotic consumption in Brazil and Mexico. PLoS ONE. 2013;8:e75550.
Not in our library10.1371/journal.pone.0075550
308.
Moura M.L., Boszczowski I., Mortari N., Barrozo L.V., Chiaravalloti Neto F., Lobo R.D., de Lima A.C., Levin A.S. The Impact of Restricting Over-the-Counter Sales of Antimicrobial Drugs: Preliminary Analysis of National Data. Medicine. 2015;94:e1605.
Not in our library10.1097/md.0000000000001605
309.
Lopes-Júnior R., de Sa Del Fiol F., Araujo J.L.O., De Toledo M.I., Barberato-Filho S. Decrease in Penicillin Sales in Brazil after Over-the-Counter Restrictions. Antimicrob. Agents Chemother. 2015;59:5862-5863.
Not in our library10.1128/aac.01030-15
310.
Mattos K.P.H., Visacri M.B., Quintanilha J.C.F., Lloret G.R., Cursino M.A., Levin A.S., Levy C.E., Moriel P. Brazil’s resolutions to regulate the sale of antibiotics: Impact on consumption and Escherichia coli resistance rates. J. Glob. Antimicrob. Resist. 2017;10:195-199.
Not in our library10.1016/j.jgar.2017.05.023
311.
Arparsrithongsagul S., Kulsomboon V., Zuckerman I.H. Multidisciplinary Perspective Intervention with Community Involvement to Decrease Antibiotic Sales in Village Groceries in Thailand. Asia Pac. J. Public Health. 2013;27:NP2480-NP2488.
Not in our library10.1177/1010539513479968
312.
Markovic-Pekovic V., Grubisa N. Self-medication with antibiotics in the Republic of Srpska community pharmacies: Pharmacy staff behavior. Pharmacoepidemiol. Drug Saf. 2012;21:1130-1133.
Not in our library10.1002/pds.3218
313.
Opanga S.A., Rizvi N., Wamaitha A., Sefah I.A., Godman B. Availability of Medicines in Community Pharmacy to Manage Patients with COVID-19 in Kenya; Pilot Study and Implications. Sch. Acad. J. Pharm. 2021;10:36-42.
Not in our library
314.
Roque F., Soares S., Breitenfeld L., López-Durán A., Figueiras A., Herdeiro M.T. Attitudes of community pharmacists to antibiotic dispensing and microbial resistance: A qualitative study in Portugal. Int. J. Clin. Pharm. 2013;35:417-424.
Not in our library10.1007/s11096-013-9753-4
315.
Barker A.K., Brown K., Ahsan M., Sengupta S., Safdar N. What drives inappropriate antibiotic dispensing? A mixed-methods study of pharmacy employee perspectives in Haryana, India. BMJ Open. 2017;7:e013190.
Not in our library10.1136/bmjopen-2016-013190
316.
Hassali M.A., Kamil T.K.T., Md Yusof F.A., Alrasheedy A.A., Yusoff Z.M., Saleem F., Al-Tamimi S.K., Wong Z.Y., Aljadhey H., Godman B. General practitioners’ knowledge, attitude and prescribing of antibiotics for upper respiratory tract infections in Selangor, Malaysia: Findings and implications. Expert Rev. Anti-Infect. Ther. 2015;13:511-520.
Not in our library10.1586/14787210.2015.1012497
317.
McNulty C.A.M., Nichols T., French D.P., Joshi P., Butler C.C. Expectations for consultations and antibiotics for respiratory tract infection in primary care: The RTI clinical iceberg. Br. J. Gen. Pract. 2013;63:e429-e436.
Not in our library10.3399/bjgp13x669149
318.
Cross E.L., Tolfree R., Kipping R. Systematic review of public-targeted communication interventions to improve antibiotic use. J. Antimicrob. Chemother. 2016;72:975-987.
Not in our library10.1093/jac/dkw520
319.
Lim K.K., Teh C.C. A Cross Sectional Study of Public Knowledge and Attitude towards Antibiotics in Putrajaya, Malaysia. South. Med. Rev. 2012;5:26-33.
Not in our library
320.
McCullough A.R., Parekh S., Rathbone J., Del Mar C.B., Hoffmann T.C. A systematic review of the public’s knowledge and beliefs about antibiotic resistance. J. Antimicrob. Chemother. 2016;71:27-33.
Not in our library10.1093/jac/dkv310
321.
Rather I.A., Kim B.-C., Bajpai V.K., Park Y.-H. Self-medication and antibiotic resistance: Crisis, current challenges, and prevention. Saudi J. Biol. Sci. 2017;24:808-812.
Not in our library10.1016/j.sjbs.2017.01.004
322.
Monnet D.L., Safrany N., Heine N., Price C. Comment on: A systematic review of the public’s knowledge and beliefs about antibiotic resistance. J. Antimicrob. Chemother. 2016;71:2364-2365.
Not in our library10.1093/jac/dkw141
323.
Barker A.K., Brown K., Ahsan M., Sengupta S., Safdar N. Social determinants of antibiotic misuse: A qualitative study of community members in Haryana, India. BMC Public Health. 2017;17:333.
Not in our library10.1186/s12889-017-4261-4
324.
Elong Ekambi G.-A., Okalla Ebongue C., Penda I.C., Nnanga Nga E., Mpondo Mpondo E., Eboumbou Moukoko C.E. Knowledge, practices and attitudes on antibiotics use in Cameroon: Self-medication and prescription survey among children, adolescents and adults in private pharmacies. PLoS ONE. 2019;14:e0212875.
Not in our library10.1371/journal.pone.0212875
325.
Ashiru-Oredope D., Hopkins S. Antimicrobial resistance: Moving from professional engagement to public action. J. Antimicrob. Chemother. 2015;70:2927-2930.
Not in our library10.1093/jac/dkv297
326.
Shallcross L.J., Howard S.J., Fowler T., Davies S.C. Tackling the threat of antimicrobial resistance: From policy to sustainable action. Philos. Trans. R. Soc. B Biol. Sci. 2015;370:20140082.
Not in our library10.1098/rstb.2014.0082
327.
Behaviour Change for Antibiotic Prescribing in Healthcare Settings. Literarure Review and Behavioural Analysis.
Not in our library
328.
WHO Collaborating Centre on Patient Safety. The University of Geneva Hospitals and Faculty of Medicine. Evaluation of Antibiotic Awareness Campaigns.
Not in our library
329.
Ivanovska V., Angelovska B., Van Dijk L., Zdravkovska M., Leufkens H.G., Mantel-Teeuwisse A.K. Change in parental knowledge, attitudes and practice of antibiotic use after a national intervention programme. Eur. J. Public Health. 2018;28:724-729.
Not in our library10.1093/eurpub/ckx240
330.
Huttner B., Goossens H., Verheij T., Harbarth S. Characteristics and outcomes of public campaigns aimed at improving the use of antibiotics in outpatients in high-income countries. Lancet Infect. Dis. 2010;10:17-31.
Not in our library10.1016/s1473-3099(09)70305-6
331.
Doctors and local media: a synergy for public health information? A controlled trial to evaluate the effects of a multifaceted campaign on antibiotic prescribing (protocol) · 2011
Not checked
332.
Hornik R., Kelly B. Communication and diet: An overview of experience and principles. J. Nutr. Educ. Behav. 2007;39(Suppl. 2):S5-S12.
Not in our library10.1016/j.jneb.2006.08.020
333.
Ali A.O.A., Prins M.H. Disease and treatment-related factors associated with tuberculosis treatment default in Khartoum State, Sudan: A case-control study. East. Mediterr. Health J. 2017;23:408-414.
Not in our library10.26719/2017.23.6.408
334.
Ambaw A.D., Alemie G.A., W/Yohannes S.M., Mengesha Z.B. Adherence to antihypertensive treatment and associated factors among patients on follow up at University of Gondar Hospital, Northwest Ethiopia. BMC Public Health. 2012;12:282.
Not in our library10.1186/1471-2458-12-282
335.
Mehra M., Cossrow N., Kambili C., Underwood R., Makkar R., Potluri R. Assessment of tuberculosis burden in China using a dynamic disease simulation model. Int. J. Tuberc. Lung Dis. Off. J. Int. Union Tuberc. Lung Dis. 2013;17:1186-1194.
Not in our library10.5588/ijtld.12.0959
336.
National Department of Health Republic of South Africa. Introduction of New Drugs and Drug Regimens for the Management of Drug Resistant Tuberculosis in South Africa: Policy Framework.
Not in our library
337.
Edwards A., Oh H., Mircheva I., Hollander C., Joubert K., Schellack N. An Ototoxicity Grading System Within a Mobile App (OtoCalc) for a Resource-Limited Setting to Guide Grading and Management of Drug-Induced Hearing Loss in Patients with Drug-Resistant Tuberculosis: Prospective, Cross-Sectional Case Series. JMIR Mhealth Uhealth. 2020;8:e14036.
Not in our library10.2196/14036
338.
Knight S.E., Anyachebelu E.J., Geddes R., Maharaj R. Impact of delayed introduction of sulfadoxine-pyrimethamine and arthemeter-lumefantrine on malaria epidemiology in KwaZulu-Natal, South Africa. Trop. Med. Int. Health. 2009;14:1086-1092.
Not in our library10.1111/j.1365-3156.2009.02333.x
339.
Phillips A.N., Stover J., Cambiano V., Nakagawa F., Jordan M.R., Pillay D., Doherty M., Revill P., Bertagnolio S. Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub–Saharan Africa. J. Infect. Dis. 2017;215:1362-1365.
Not in our library10.1093/infdis/jix089
340.
Banek K., Webb E.L., Smith S.J., Chandramohan D., Staedke S.G. Adherence to treatment with artemether—Lumefantrine or amodiaquine—Artesunate for uncomplicated malaria in children in Sierra Leone: A randomized trial. Malar. J. 2018;17:222.
Not in our library10.1186/s12936-018-2370-x
341.
Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies · 2018
No notice
342.
Becker N., Cordeiro L.S., Poudel K.C., Sibiya T.E., Sayer A.G., Sibeko L.N. Individual, household, and community level barriers to ART adherence among women in rural Eswatini. PLoS ONE. 2020;15:e0231952.
Not in our library10.1371/journal.pone.0231952
343.
The Impact of mHealth Interventions: Systematic Review of Systematic Reviews · 2018
No notice
344.
Stephens F., Gandhi N.R., Brust J.C.M., Mlisana K., Moodley P., Allana S., Campbell A., Shah S. Treatment Adherence among Persons Receiving Concurrent Multidrug-Resistant Tuberculosis and HIV Treatment in KwaZulu-Natal, South Africa. J. Acquir. Immune Defic. Syndr. 2019;82:124-130.
Not in our library10.1097/qai.0000000000002120
345.
Mekonnen H.S., Azagew A.W. Non-adherence to anti-tuberculosis treatment, reasons and associated factors among TB patients attending at Gondar town health centers, Northwest Ethiopia. BMC Res. Notes. 2018;11:691.
Not in our library10.1186/s13104-018-3789-4
346.
Survey of antiretroviral therapy adherence and predictors of poor adherence among HIV patients in a tertiary institution in Nigeria · 2019
Not checked
347.
Moomba K., Van Wyk B. Social and economic barriers to adherence among patients at Livingstone General Hospital in Zambia. Afr. J. Prim. Health Care Fam. Med. 2019;11:e1-e6.
Not in our library10.4102/phcfm.v11i1.1740
348.
Vagiri R.V., Meyer J.C., Godman B., Gous A.G.S. Relationship between adherence and health-related quality of life among HIV-patients in South Africa: Findings and implications. J. AIDS HIV Res. 2018;10:121-132.
Not in our library
349.
Baxter C., Karim A.S.S. Recent Advances and the Prospect of an HIV Cure.
Not in our library
350.
Multistage and transmission-blocking targeted antimalarials discovered from the open-source MMV Pandemic Response Box · 2021
Not checked
351.
Adam H.J., Richardson S.E., Jamieson F.B., Rawte P., Low D.E., Fisman D.N. Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: Evidence for herd effects and strain replacement due to Hib vaccination. Vaccine. 2010;28:4073-4078.
Not in our library10.1016/j.vaccine.2010.03.075
352.
Heilmann K.P., Rice C.L., Miller A.L., Miller N.J., Beekmann S.E., Pfaller M.A., Richter S.S., Doern G.V. Decreasing prevalence of beta-lactamase production among respiratory tract isolates of Haemophilus influenzae in the United States. Antimicrob. Agents Chemother. 2005;49:2561-2564.
Not in our library10.1128/aac.49.6.2561-2564.2005
353.
Cohen R., Cohen J.F., Chalumeau M., Levy C. Impact of pneumococcal conjugate vaccines for children in high- and non-high-income countries. Expert Rev. Vaccines. 2017;16:625-640.
Not in our library10.1080/14760584.2017.1320221
354.
Tomczyk S.M., Lynfield R., Schaffner W., Reingold A., Miller L., Petit S., Holtzman C., Zansky S.M., Thomas A., Baumbach J., et al. Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine. Clin. Infect. Dis. 2016;62:1119-1125.
Not in our library10.1093/cid/ciw067
355.
Impact of Ten-Valent Pneumococcal Conjugate Vaccination on Invasive Pneumococcal Disease in Finnish Children – A Population-Based Study · 2015
No notice
356.
Lewnard J.A., Lo N.C., Arinaminpathy N., Frost I., Laxminarayan R. Childhood vaccines and antibiotic use in low- and middle-income countries. Nature. 2020;581:94-99.
Not in our library10.1038/s41586-020-2238-4
357.
Czech M., Balcerzak M., Antczak A., Byliniak M., Piotrowska-Rutkowska E., Drozd M., Juszczyk G., Religioni U., Vaillancourt R., Merks P. Flu Vaccinations in Pharmacies—A Review of Pharmacists Fighting Pandemics and Infectious Diseases. Int. J. Environ. Res. Public Health. 2020;17:7945.
Not in our library10.3390/ijerph17217945
358.
WHO. Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance: An Action Framework—Annex to Immunization Agenda 2030. 2020.
Not in our library
359.
Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance: A World Health Organization Action Framework · 2021
No notice
360.
COVID-19 vaccine hesitancy in the UK: the Oxford coronavirus explanations, attitudes, and narratives survey (Oceans) II · 2020
No notice
361.
Lewandowsky S., Cook J., Schmid P., Holford D.L., Finn A., Leask J., Thomson A., Lombardi D., Al-Rawi A.K., Amazeen M.A., et al. The COVID-19 Vaccine Communication Handbook. A Practical Guide for Improving Vaccine Communication and Fighting Misinformation. 2021.
Not in our library
362.
Wood T. Twitter to Start Banning Accounts That Spread Covid-19 Vaccine Misinformation.
Not in our library
363.
WHO. Countering Misinformation about COVID-19. 2020.
Not in our library
364.
UK Government. Community Champions to Give COVID-19 Vaccine Advice and Boost Take Up. 2021.
Not in our library
365.
Igoe M. UN Harassment, COVID-19 Misinformation, and Vaccine Efficacy: This Week in Development.
Not in our library
366.
WHO. Patient Engagement: Technical Series on Safer Primary Care. 2016.
Not in our library
367.
The British Psychological Society. Delivering Effective Public Health Campaigns during Covid-19. 2020.
Not in our library
368.
Charan J., Kaur R.J., Bhardwaj P., Haque M., Sharma P., Misra S., Godman B. Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications. Expert Rev. Clin. Pharm. 2021;14:95-103.
Not in our library10.1080/17512433.2021.1856655
369.
Dyer O. Covid-19: Remdesivir has little or no impact on survival, WHO trial shows. BMJ. 2020;371:m4057.
Not in our library10.1136/bmj.m4057
370.
WHO. WHO Discontinues Hydroxychloroquine and Lopinavir/Ritonavir Treatment Arms for COVID-19. 2020.
Not in our library
371.
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 · 2020
No notice
372.
Cao B., Wang Y., Wen D., Liu W., Wang J., Fan G., Ruan L., Song B., Cai Y., Wei M., et al. A Trial of Lopinavir—Ritonavir in Adults Hospitalized with Severe Covid-19. N. Engl. J. Med. 2020;382:1787-1799.
Not in our library10.1056/nejmoa2001282
373.
Recovery Trial. Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on Lopinavir-Ritonavir, 29 June 2020. No Clinical Benefit from Use of Lopinavir-Ritonavir in Hospitalised COVID-19 Patients Studied in RECOVERY.
Not in our library
374.
Council for International Organizations of Medical Sciences. Medicines Assessment during Public Health Emergencies Needs Good Science, Best Practices and Proper Communication. 2020.
Not in our library
375.
Zahlanie Y., Mang N.S., Lin K., Hynan L.S., Prokesch B.C. Improved Antibiotic Prescribing Practices for Respiratory Infections Through Use of Computerized Order Sets and Educational Sessions in Pediatric Clinics. Open Forum Infect. Dis. 2021;8:ofaa601.
Not in our library10.1093/ofid/ofaa601
376.
Holstiege J., Mathes T., Pieper D. Effects of computer-aided clinical decision support systems in improving antibiotic prescribing by primary care providers: A systematic review. J. Am. Med. Inform. Assoc. 2015;22:236-242.
Not in our library10.1136/amiajnl-2014-002886
377.
Riaz H., Godman. B.; Hussain, S.; Malik, F.; Mahmood, S.; Shami, A.; Bashir, S. Prescribing of bisphosphonates and antibiotics in Pakistan: Challenges and opportunities for the future. JPHSR. 2015;6:111-121.
Not in our library
378.
Fadare J.O., Oshikoya K.A., Ogunleye O.O., Desalu O.O., Ferrario A., Enwere O.O., Adeoti A., Sunmonu T.A., Massele A., Baker A., et al. Determinants of antibiotic prescribing among doctors in a Nigerian urban tertiary hospital. Hosp. Pract. 2018;47:53-58.
Not in our library10.1080/21548331.2018.1475997
379.
Fadare J.O., Oshikoya K.A., Ogunleye O.O., Desalu O.O., Ferrario A., Enwere O.O., Adeoti A., Sunmonu T.A., Massele A., Baker A., et al. Drug promotional activities in Nigeria: Impact on the prescribing patterns and practices of medical practitioners and the implications. Hosp. Pract. 2018;46:77-87.
Not in our library10.1080/21548331.2018.1437319
380.
Adepoju I.-O.O., Albersen B.J.A., De Brouwere V., Van Roosmalen J., Zweekhorst M. mHealth for Clinical Decision-Making in Sub-Saharan Africa: A Scoping Review. JMIR Mhealth Uhealth. 2017;5:e38.
Not in our library10.2196/mhealth.7185
381.
Birjovanu G., Lefevre C., Hayward A., Molnar A., Ncube F., Wiseman S., Kostkova P., Wood C., Olufemi O., Ogunsola F., et al. GADSA: Decision Support App for Antibiotics Prescribing in Nigeria. Proceedings of the 9th International Conference on Digital Public Health. 9-10.
Not in our library
382.
Investigating the cultural and contextual determinants of antimicrobial stewardship programmes across low-, middle- and high-income countries—A qualitative study · 2019
No notice
383.
Miljković N., Godman B., van Overbeeke E., Kovačević M., Tsiakitzis K., Apatsidou A., Nikopoulou A., Yubero C.G., Horcajada L.P., Stemer G., et al. Risks in Antibiotic Substitution Following Medicine Shortage: A Health-Care Failure Mode and Effect Analysis of Six European Hospitals. Front. Med. 2020;7.
Not in our library10.3389/fmed.2020.00157
384.
Prospective Risk Assessment of Medicine Shortages in Europe and Israel: Findings and Implications · 2020
Not checked
385.
Afriyie D.K., Asare G.A., Amponsah S.K., Godman B. COVID-19 pandemic in resource-poor countries: Challenges, experiences and opportunities in Ghana. J. Infect. Dev. Ctries. 2020;14:838-843.
Not in our library10.3855/jidc.12909
386.
Björkhem-Bergman L., Andersén-Karlsson E., Laing R., Diogene E., Melien O., Jirlow M., Malmström R.E., Vogler S., Godman B., Gustafsson L.L. Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. Eur. J. Clin. Pharm. 2013;69:73-78.
Not in our library10.1007/s00228-013-1497-5
387.
Yoon C.H., Ritchie S.R., Duffy E.J., Thomas M.G., McBride S., Read K., Chen R., Humphrey G. Impact of a smartphone app on prescriber adherence to antibiotic guidelines in adult patients with community acquired pneumonia or urinary tract infections. PLoS ONE. 2019;14:e0211157.
Not in our library10.1371/journal.pone.0211157
388.
Eriksen J., Gustafsson L.L., Ateva K., Bastholm-Rahmner P., Ovesjo M.L., Jirlow M., Juhasz-Haverinen M., Lärfars G., Malmström R.E., Wettermark B., et al. High adherence to the ‘Wise List’ treatment recommendations in Stockholm: A 15-year retrospective review of a multifaceted approach promoting rational use of medicines. BMJ Open. 2017;7:e014345.
Not in our library10.1136/bmjopen-2016-014345
389.
Gustafsson L.L., Wettermark B., Godman B., Andersén-Karlsson E., Bergman U., Hasselström J., Hensjö L.-O., Hjemdahl P., Jägre I., Julander M., et al. The ‘Wise List’—A Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in Stockholm. Basic Clin. Pharm. Toxicol. 2011;108:224-233.
Not in our library10.1111/j.1742-7843.2011.00682.x
390.
Klein E.Y., Milkowska-Shibata M., Tseng K.K., Sharland M., Gandra S., Pulcini C., Laxminarayan R. Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000–2015: An analysis of pharmaceutical sales data. Lancet Infect. Dis. 2021;21:107-115.
Not in our library10.1016/s1473-3099(20)30332-7
391.
Lorencatto F., Charani E., Sevdalis N., Tarrant C., Davey P. Driving sustainable change in antimicrobial prescribing practice: How can social and behavioural sciences help? J. Antimicrob. Chemother. 2018;73:2613-2624.
Not in our library10.1093/jac/dky222
392.
Sharland M., Pulcini C., Harbarth S., Zeng M., Gandra S., Mathur S., Magrini N. Classifying antibiotics in the WHO Essential Medicines List for optimal use—Be AWaRe. Lancet Infect. Dis. 2018;18:18-20.
Not in our library10.1016/s1473-3099(17)30724-7
393.
Hsia Y., Sharland M., Jackson C., Wong I.C.K., Magrini N., Bielicki J.A. Consumption of oral antibiotic formulations for young children according to the WHO Access, Watch, Reserve (AWaRe) antibiotic groups: An analysis of sales data from 70 middle-income and high-income countries. Lancet Infect. Dis. 2019;19:67-75.
Not in our library10.1016/s1473-3099(18)30547-4
394.
Mwita S.J.M., Marwa K., Hamasaki K., Katabalo D., Burger J., Godman B., Ferrario A., Massele A., Ruganuza D. Medicines dispensers’ knowledge on the implementation of an artemisinin-based combination therapy policy for the treatment of uncomplicated malaria in Tanzania. J. Pharm. Health Serv. Res. 2017;8:227-233.
Not in our library10.1111/jphs.12187

Cited by papers we hold 1

An Overview of the Recent Advances in Antimicrobial Resistance · 2024
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.